<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Platinum‐containing regimens for triple‐negative metastatic breast cancer - Egger, SJ - 2020 | Cochrane Library</title> <meta content="Platinum‐containing regimens for triple‐negative metastatic breast cancer - Egger, SJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013750/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Platinum‐containing regimens for triple‐negative metastatic breast cancer - Egger, SJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013750/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013750" name="dc.identifier" scheme="DOI"/> <meta content="Platinum‐containing regimens for triple‐negative metastatic breast cancer" name="citation_title"/> <meta content="Sam J Egger" name="citation_author"/> <meta content="Cancer Council NSW" name="citation_author_institution"/> <meta content="same@nswcc.org.au" name="citation_author_email"/> <meta content="Matthew Ming Ki Chan" name="citation_author"/> <meta content="Gosford Hospital" name="citation_author_institution"/> <meta content="Qingwei Luo" name="citation_author"/> <meta content="Cancer Council NSW" name="citation_author_institution"/> <meta content="Nicholas Wilcken" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD013750" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013750/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013750/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013750/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [adverse effects, *therapeutic use]; Bias; Carboplatin [adverse effects, *therapeutic use]; Cisplatin [adverse effects, *therapeutic use]; Genes, BRCA1; Genes, BRCA2; Nausea [chemically induced]; Oxaliplatin [adverse effects, *therapeutic use]; Progression-Free Survival; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms [*drug therapy, genetics, mortality]; Vomiting [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013750&amp;doi=10.1002/14651858.CD013750&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013750\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013750\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013750",title:"Platinum\\u2010containing regimens for triple\\u2010negative metastatic breast cancer",firstPublishedDate:"Oct 21, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013750&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013750';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013750/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013750/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013750%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013750/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013750/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013750/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013750/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013750" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013750/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013750" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013750/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013750/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4095 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013750" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0071"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013750/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/appendices#CD013750-sec-0076"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/supinfo/CD013750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/supinfo/CD013750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013750/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013750/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013750/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013750/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013750/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Platinum‐containing regimens for triple‐negative metastatic breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013750/information#CD013750-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sam J Egger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013750/information#CD013750-cr-0005">Matthew Ming Ki Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013750/information#CD013750-cr-0006">Qingwei Luo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013750/information#CD013750-cr-0007">Nicholas Wilcken</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013750/information/en#CD013750-sec-0085">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013750/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013750">https://doi.org/10.1002/14651858.CD013750</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013750-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013750-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013750-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013750-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013750-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013750-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013750-abs-0001" lang="en"> <section id="CD013750-sec-0001"> <h3 class="title" id="CD013750-sec-0001">Background</h3> <p>In a previous Cochrane Review, we found that for women with metastatic breast cancer unselected for triple‐negative disease, there is little or no survival benefit and excess toxicity from platinum‐based regimens. In subgroup analyses, however, we found preliminary low‐quality evidence of a survival benefit from platinum‐based regimens for women with metastatic triple‐negative breast cancer (mTNBC). This review updates the evidence from the mTNBC subgroup analyses in the previous Cochrane Review. </p> </section> <section id="CD013750-sec-0002"> <h3 class="title" id="CD013750-sec-0002">Objectives</h3> <p>To assess the effects of platinum‐containing chemotherapy regimens with regimens not containing platinum in the management of women with mTNBC. </p> </section> <section id="CD013750-sec-0003"> <h3 class="title" id="CD013750-sec-0003">Search methods</h3> <p>We obtained relevant studies published prior to 2015 and their extracted results from the mTNBC subgroup analysis in the previous Cochrane Review. We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov between 2015 and 27 September 2019. We identified further potentially relevant studies from previous trial reports, systematic reviews, and meta‐analyses. </p> </section> <section id="CD013750-sec-0004"> <h3 class="title" id="CD013750-sec-0004">Selection criteria</h3> <p>Randomised trials comparing platinum‐containing chemotherapy regimens with regimens not containing platinum in women with mTNBC. Individual trials could compare one or more platinum‐based regimens to one or more non‐platinum regimens; hence there could be more 'treatment‐comparisons' (i.e. platinum regimen versus non‐platinum regimen comparison) than trials. Trial participants may have been purposely selected for mTNBC or inadvertently selected as a subgroup. </p> </section> <section id="CD013750-sec-0005"> <h3 class="title" id="CD013750-sec-0005">Data collection and analysis</h3> <p>At least two independent reviewers assessed studies for eligibility and quality, and extracted all relevant data from each study. We derived hazard ratios (HRs) for time‐to‐event outcomes, where possible, and used fixed‐effect models for meta‐analyses. We analysed objective tumour response rates (OTRRs) and toxicities as binary (dichotomous) outcomes with risk ratios (RRs) used as measures of effects. We extracted quality of life data, if available. We used GRADE to rate the quality of evidence for time‐to‐event and tumour response outcomes. </p> </section> <section id="CD013750-sec-0006"> <h3 class="title" id="CD013750-sec-0006">Main results</h3> <p>This review includes 13 treatment‐comparisons involving 1349 women from 10 studies. Twelve of the 13 treatment‐comparisons were included in one or more meta‐analyses. Of the 13 treatment‐comparisons, six and eight had published or provided time‐to‐event data on overall survival (OS) or progression‐free survival/time to progression (PFS/TTP), respectively, that could be included in meta‐analyses. Ten treatment‐comparisons published or provided OTRR data that could be included in meta‐analyses. Eight of the 13 treatment‐comparisons were from studies that selected participants on the basis of mTNBC status, while the other five treatment‐comparisons were from studies that reported mTNBC results as part of subgroup analyses. </p> <p>Analysis of six treatment‐comparisons indicated that platinum‐containing regimens may have provided a small survival benefit to mTNBC patients (HR 0.85, 95% CI 0.73 to 1.00; 958 women; moderate‐quality evidence) with no evidence of heterogeneity (P = 0.41; I<sup>2</sup> = 1%). Data from eight treatment‐comparisons showed that platinum regimens may improve PFS/TTP (HR 0.77, 95% CI 0.68 to 0.88; 1077 women; very low‐quality evidence). There was marked evidence of heterogeneity (P &lt; 0.0001; I<sup>2</sup> = 80%). There was also low‐quality evidence of better tumour response for platinum recipients (RR 1.40, 95% CI 1.22 to 1.59; 1205 women) with some evidence of heterogeneity (P = 0.01; I<sup>2</sup> = 58%). The observed heterogeneity for the PFS/TTP and OTRR outcomes may reflect between‐study differences and general difficulties in assessing tumour response, as well as the varying potencies of the comparators. </p> <p>Compared with women receiving non‐platinum regimens: rates of grade 3 and 4 nausea/vomiting were higher for platinum recipients (RR 4.77, 95% CI 1.93 to 11.81; 655 women; low‐quality evidence) and rates of grade 3 and 4 anaemia were higher for platinum recipients (RR 3.80, 95% CI 2.25 to 6.42; 843 women; low‐quality evidence). In general, however, relatively few intervention‐comparisons could be included in meta‐analyses for adverse events. None of the studies reported quality of life. </p> </section> <section id="CD013750-sec-0007"> <h3 class="title" id="CD013750-sec-0007">Authors' conclusions</h3> <p>For women with mTNBC, there was moderate‐quality evidence of a small survival benefit from platinum‐based regimens compared to non‐platinum regimens. This finding is consistent with findings of a PFS/TTP benefit and improved tumour response from platinum‐based regimens. These potential benefits, however, should be weighed against previously identified excess toxicities from platinum‐based regimens, particularly regimens containing cisplatin. Further randomised trials of platinum‐based regimens among women with mTNBC are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013750-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013750-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013750-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013750-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013750-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013750-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013750-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013750-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013750-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013750-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013750-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013750-abs-0002" lang="en"> <h3>Platinum‐containing regimens for triple‐negative metastatic breast cancer</h3> <p><b>What is the issue?</b> </p> <p>Metastatic breast cancer occurs when the cancer has spread to areas of the body beyond the breast and nearby lymph nodes. Although metastatic breast cancer is generally not curable, it is widely accepted that women with metastatic disease should receive some form of chemotherapy to help ease the severity of disease symptoms, slow cancer progression and improve survival, when compared to no treatment. Chemotherapy containing platinum is known to be effective for treating a number of cancer types including lung, testicular, head and neck, bladder and ovarian cancers. However, it is also known to cause more adverse effects (such as nausea and vomiting, hair loss, anaemia, kidney damage and low white blood cells) than other chemotherapy options. The two platinum agents most used for treating metastatic breast cancer are carboplatin and cisplatin. </p> <p>In a previous Cochrane Review, we found that for women with metastatic breast cancer, there is little or no survival benefit, and more side effects related to toxicity, from platinum‐based regimens. In analysing different groups of women with metastatic disease, however, we found preliminary evidence of a survival benefit from platinum‐based regimens for women with the triple‐negative subtype of metastatic breast cancer. The term 'triple‐negative' relates to the fact that this subtype of breast cancer tests negative for oestrogen receptors (ERs) and progesterone receptors (PgRs), and have low levels of a protein called human epidermal growth factor receptor 2 (HER2). </p> <p>The current review updates the evidence on platinum‐containing regimens for women with a specific breast cancer subtype of triple‐negative metastatic breast cancer (mTNBC). </p> <p><b>Why does it matter?</b> </p> <p>mTNBC makes up approximately 12% to 17% of breast cancers and is associated with shorter survival and higher chance that the cancer returns. In recent years, some researchers have hypothesised that chemotherapy containing platinum might be more effective in treating mTNBC than other chemotherapy options. Randomised controlled trials (RCTs) have been designed and conducted to test this hypothesis. </p> <p><b>We asked:</b> </p> <p>Are chemotherapy treatments containing a platinum agent more or less effective for treating women with mTNBC than chemotherapy treatments not containing a platinum agent? </p> <p><b>We found:</b> </p> <p>10 studies involving 1349 women. The evidence is current to September 2019. This review found that for women with mTNBC, a chemotherapy containing platinum: </p> <p>‐ may increase survival time over chemotherapy without platinum;</p> <p>‐ reduces the number of breast cancer recurrences compared to chemotherapy that did not contain platinum but we are uncertain about these results; </p> <p>‐ appears to cause tumours to shrink more than chemotherapy without platinum;</p> <p>‐ may increase the chance of severe nausea and vomiting compared to treatment without platinum; and </p> <p>‐ may increase the chance of anaemia compared to chemotherapy without platinum.</p> <p><b>What does this mean?</b> </p> <p>Chemotherapy containing platinum may provide a small survival benefit to mTNBC participants, but still large enough to justify its use. This potential benefit needs to be weighed against the higher risks of toxic side effects from platinum‐based regimens compared to non‐platinum regimens. Further studies are required before a more definitive conclusion can be made. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013750-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013750-sec-0071"></div> <h3 class="title" id="CD013750-sec-0072">Implications for practice</h3> <section id="CD013750-sec-0072"> <p>The main findings in this review are broadly similar to the mTNBC subgroup findings in our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>). In particular, this review found moderate‐quality evidence of a small survival benefit from platinum‐based regimens for women with mTNBC. While it remains unclear whether the possible benefits for women with mTNBC are related to the type of platinum agent, evidence from our previous review suggested that carboplatin was generally associated with less toxicity than cisplatin. Given the similarity of the findings in this review with those from our previous review, we find no compelling reason for changing our previous conclusions. That is, we believe the current evidence suggests that it may be premature to recommend widespread use of platinum‐based regimens for mTNBC patients given the excess toxicity associated with such regimens. Nonetheless, some women and clinicians may consider platinum‐based regimens worth trying given that nausea and vomiting can be manageable with modern antiemetics, and that carboplatin can be a less toxic alternative to cisplatin. </p> </section> <h3 class="title" id="CD013750-sec-0073">Implications for research</h3> <section id="CD013750-sec-0073"> <p>Our finding of a small survival benefit from platinum‐based regimens for women with mTNBC was based on moderate‐quality evidence from only six trials with 958 women; hence, additional randomised trials are necessary to confirm this finding. In addition, as we discuss above, BRCA1/2 subgroup results suggest that a useful line of research might be BRCA1/2 testing and subgroup analysis in future trials assessing platinum chemotherapies for mTNBC patients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013750-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013750-sec-0008"></div> <div class="table" id="CD013750-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum compared to non‐platinum regimens for metastatic triple‐negative breast cancer: OS, PFS/TTP and OTRR</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> platinum<br/><b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platinum containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.85<br/>(0.73 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>958<br/>(6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: Chi² = 5.05, df = 5 (P = 0.41); I² 1%</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>510 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>455 per 1,000<br/>(406 to 510)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>711 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1,000<br/>(596 to 711)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (PFS/TTP)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of progression or death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.77<br/>(0.68 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1077<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: Chi² = 34.78, df = 7 (P &lt; 0.0001); I² 80%</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>936 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>880 per 1,000<br/>(846 to 911)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2‐year risk of progression or death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>970 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1,000<br/>(908 to 954)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (OTRR) (assessable participants)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1,000 <sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1,000<br/>(449 to 585) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(1.22 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1205<br/>(10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: Chi² = 21.44, df = 9 (P = 0.01); I² 58%</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b> (⊕⊕⊕⊕): We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> (⊕⊕⊕⊝)<b>:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> (⊕⊕⊝⊝)<b>:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b> (⊕⊝⊝⊝ or ⊝⊝⊝⊝)<b>:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p>Each ⊝ symbol represents a downgrading of the quality of evidence one level from the highest level of 'high quality (⊕⊕⊕⊕).' </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the 3 highest weighted treatment‐comparisons in <a href="./references#CD013750-fig-0009" title="">Analysis 1.1</a>. </p> <p><sup>2</sup>Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD013750-bbs2-0046" title="GuyattGH , JuniperEF , WalterSD , GriffithLE , GoldsteinRS . Interpreting treatment effects in randomised trials. BMJ 1998 Feb 28;316(7132):499-501.">Guyatt 1998</a>) </p> <p><sup>3</sup>Downgraded quality of evidence one level for ’serious imprecision’ because the confidence interval for the pooled estimate is wide and crosses or nearly crosses unity. </p> <p><sup>4</sup>Downgraded quality of evidence one level for ’serious indirectness’ because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD013750-bbs2-0034" title="BurzykowskiT , BuyseM , Piccart-GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987-92.">Burzykowski 2008</a>). </p> <p><sup>5</sup>Downgraded quality of evidence one level for ’serious inconsistency’ because there was substantial evidence of heterogeneity. </p> <p><sup>6</sup>Downgraded quality of evidence one level for suspected publication bias (forest plot asymmetry). </p> <p><sup>7</sup>Estimated from all 10 mTNBC treatment‐comparisons in the review with OTRR results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013750-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for treatment related death, nausea/vomiting, nephrotoxicity, anaemia, hair loss, leuko</b> paenia<b>and treatment discontinuation due to adverse event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> platinum<br/><b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platinum containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐related death (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1,000<br/>(1 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 1.06, 95% CI 0.24 to 4.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.69, I<sup>2</sup> 0% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting* grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/>(29 to 177) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(RR 4.77, 95% CI 1.93 to 11.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>655 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.32, I<sup>2</sup> 12% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nephrotoxicity (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trials reported this outcome for mTNBC patients.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaemia grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000<br/>(81 to 231) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(RR 3.80, 95% CI 2.25 to 6.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.04, I<sup>2</sup> 65% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hair loss (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1,000<br/>(0 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 0.33, 95% CI 0.01 to 8.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopaenia (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>155 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>169 per 1000 (130 to 220)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 1.09, 95% CI 0.84 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.75, I<sup>2</sup> 0% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment discontinuation due to adverse event (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>93 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 1000 (55 to 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 0.88, 95% CI 0.59 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.07, I<sup>2</sup> 57% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> (⊕⊕⊕⊕): We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> (⊕⊕⊕⊝)<b>:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> (⊕⊕⊝⊝)<b>:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b> (⊕⊝⊝⊝ or ⊝⊝⊝⊝)<b>:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p>Each ⊝ symbol represents a downgrading of the quality of evidence one level from the highest level of 'high quality (⊕⊕⊕⊕).' </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Estimated from all treatment‐comparisons contributing data for pooling for this outcome (including treatment‐comparisons with non‐estimable effects due to no events in either arm). </p> <p><sup>2</sup>Downgraded quality of evidence one level for 'serious imprecision' because the confidence interval for the pooled estimate is wide. </p> <p><sup>3</sup>Downgraded quality of evidence two levels for 'very serious imprecision' because the confidence interval for the pooled estimate is very wide. </p> <p><sup>4</sup>Downgraded quality of evidence one level for 'serious inconsistency' because there was evidence of heterogeneity across studies (P &lt; 0.05) </p> <p>*data on vomiting was included if data on nausea/vomiting was reported separately</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013750-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013750-sec-0009"></div> <section id="CD013750-sec-0010"> <h3 class="title" id="CD013750-sec-0010">Description of the condition</h3> <p>Breast cancer is both the most common type of cancer in women and the most common cause of cancer death in women (<a href="./references#CD013750-bbs2-0041" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al. (2018) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.. https://gco.iarc.fr/today accessed [17 January 2019].">Ferlay 2018a</a>). In 2018, there was an estimated 2.1 million estimated new cases and approximately 627,000 deaths from breast cancer worldwide, with an age‐standardised death rate (ASR) of 13.0 per 100,000 (<a href="./references#CD013750-bbs2-0041" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al. (2018) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.. https://gco.iarc.fr/today accessed [17 January 2019].">Ferlay 2018a</a>). In the same year, the disease was the most common cancer type in more than three‐quarters of countries worldwide and was the leading cause of cancer death in more than half of countries worldwide (<a href="./references#CD013750-bbs2-0042" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians Novemebr 2018;68(6):394-424.">Ferlay 2018b</a>). </p> <p>The stage of breast cancer at the time of diagnosis is an important indicator of prognosis. Once breast cancer becomes metastatic, it is not generally considered curable and most women with metastatic disease do not survive beyond five years from the time of their metastatic diagnosis (<a href="./references#CD013750-bbs2-0036" title="ClementsMS , RoderDM , YuXQ , EggerS , O'ConnellDL . Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap. Cancer Causes &amp; Control2012;23(10):1625-34.">Clements 2012</a>). Another important predictor of prognosis is the biological subtype of breast cancer. One of these subtypes, triple‐negative breast cancer (TNBC), is characterised by a lack of expression of oestrogen receptors (ER), progesterone receptors (PgR) and human epidermal receptor 2 (HER2). TNBC comprises approximately 12% to 17% of breast cancers and is associated with shorter survival and higher likelihood of recurrence (<a href="./references#CD013750-bbs2-0043" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. NEJM2010;363(20):1938-48.">Foulkes 2010</a>). The median survival time for women diagnosed with metastatic TNBC (mTNBC) is about one year from their metastatic diagnosis (<a href="./references#CD013750-bbs2-0052" title="KassamF , EnrightK , DentR , DranitsarisG , MyersJ , FlynnC , et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clinical Breast Cancer2009;9(1):29-33.">Kassam 2009</a>). </p> <p>Although there is no evidence from randomised trials comparing chemotherapy with observation (i.e. no chemotherapy) in women with metastatic breast cancer, it is widely accepted that women with metastatic disease should receive some form of systemic therapy at some time during the course of their metastatic disease. Chemotherapy is considered by many to be the appropriate first treatment option for women with multiple sites of recurrence or where visceral disease is not easily treated by local modalities (<a href="./references#CD013750-bbs2-0048" title="HayesDF , HendersonIC , ShapiroCL . Treatment of metastatic breast cancer: present and future prospects. Seminars in Oncology1995;22(Suppl 5):5-21.">Hayes 1995</a>; <a href="./references#CD013750-bbs2-0033" title="BeslijaS , BonneterreJ , BursteinHJ , CocquytV , GnantM , HeinemannV , et al. Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology2009;20(11):1771-85.">Beslija 2009</a>). Chemotherapy is also considered to be useful in women whose cancer is hormone refractory or is expected to be hormone resistant (<a href="./references#CD013750-bbs2-0051" title="HortobagyiGN , Piccart-GebhartMJ . Current management of advanced breast cancer. Seminars in Oncology1996;23(Suppl 11):1-5.">Hortobagyi 1996</a>). </p> </section> <section id="CD013750-sec-0011"> <h3 class="title" id="CD013750-sec-0011">Description of the intervention</h3> <p>Platinum compound, an alkylating agent, has been known to be active in metastatic breast cancer since clinical trials in the 1970s. However, it is more toxic and difficult to administer than other chemotherapy agents. The three most widely used platinum agents for treating breast cancer are cisplatin, carboplatin (both divalent complexes) and oxaliplatin (a tetravalent complex) (<a href="./references#CD013750-bbs2-0058" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1-10.">Sikov 2015</a>). Cisplatin and carboplatin have demonstrated benefits in treating a number of cancer types including lung, testicular, head and neck, bladder and ovarian cancers. Oxaliplatin is often used to treat cisplatin‐ and carboplatin‐resistant tumours because it is commonly believed that cross‐resistance between oxaliplatin and cisplatin or carboplatin is incomplete (<a href="./references#CD013750-bbs2-0054" title="ManiS , GrahamMA , BregmanDB , IvyP , ChaneySG . Oxaliplatin: a review of evolving concepts. Cancer Investigation2002;20(2):246-63.">Mani 2002</a>). More recent evidence suggests that the benefits of oxaliplatin may be due to its low toxicity and ability to be combined with other drugs rather than incomplete cross‐resistance with other platinum agents (<a href="./references#CD013750-bbs2-0059" title="StordalB , PavlakisN , DaveyR . Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews2007;33(4):347-57.">Stordal 2007</a>). </p> <p>The use of oxaliplatin for treating breast cancers is much less common than the use of cisplatin or carboplatin, both in normal clinical practice and as an intervention in clinical trials (<a href="./references#CD013750-bbs2-0058" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1-10.">Sikov 2015</a>). Cisplatin and carboplatin have been used and studied extensively as first‐line metastatic therapy in combination with other older pharmacological agents including 5‐fluorouracil and etoposide, and more recently with doxorubicin, epirubicin, vinorelbine, paclitaxel, docetaxel, cyclophosphamide, methotrexate and gemcitabine. The potential benefits of cisplatin or carboplatin as monotherapy for metastatic breast cancer, rather than as combination therapy, are rarely studied in clinical trials. </p> <p>Although platinum agents have been shown to be efficacious in the treatment of a number of cancer types, their use is often associated with a variety of side effects. The known side effects of platinum agents include nausea, vomiting, myelosuppression (thrombocytopaenia, leukopaenia, neutropaenia and anaemia), peripheral neuropathy (symptoms include tingling in fingers and toes), nephrotoxicity, ototoxicities (hearing loss and tinnitus), hypomagnesaemia and anaphylaxis. Carboplatin is reported to be more tolerable than cisplatin with less nausea and vomiting, nephrotoxicity, ototoxicity and neurotoxicity, but worse myelosuppression, especially thrombocytopaenia (<a href="./references#CD013750-bbs2-0058" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1-10.">Sikov 2015</a>). </p> </section> <section id="CD013750-sec-0012"> <h3 class="title" id="CD013750-sec-0012">How the intervention might work</h3> <p>The exact mechanism of action of platinum agents is not known but deoxyribonucleic acid (DNA) adducts are formed (<a href="./references#CD013750-bbs2-0058" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1-10.">Sikov 2015</a>). These complexes are believed to inhibit DNA synthesis, replication and transcription by forming interstrand and intrastrand cross‐linking of DNA molecules. Interstrand cross‐links that remain intact can produce cell death, and it is this cytotoxic effect, when successful, that forms the mechanistic basis of action for cancer cell death by platinum agents (<a href="./references#CD013750-bbs2-0055" title="NollDM , MasonTM , MillerPS . Formation and repair of interstrand cross-links in DNA. Chemical Reviews2006;106(2):277-301.">Noll 2006</a>). For TNBC, it has been additionally hypothesised that a dysfunctional BRCA1 pathway in some TNBCs may make them more sensitive to platinum agents that selectively target cells deficient in homologous recombination DNA repair (<a href="./references#CD013750-bbs2-0043" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. NEJM2010;363(20):1938-48.">Foulkes 2010</a>). </p> </section> <section id="CD013750-sec-0013"> <h3 class="title" id="CD013750-sec-0013">Why it is important to do this review</h3> <p>In a previous Cochrane Review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), we found high‐quality evidence of little or no survival benefit from platinum‐based regimens for women with metastatic breast cancer unselected for triple‐negative disease. In that review we concluded that in relation to platinum agents, "... it is difficult to justify their use over commonly‐available less toxic active agents as first‐line treatment for metastatic patients without mTNBC." We determined that this conclusion was unlikely to change with the inclusion of additional studies. Hence, we are no longer updating the previous review in regards to women with metastatic breast cancer, unselected for triple‐negative disease. </p> <p>However, in the previous review's subgroup analyses, we found preliminary low‐quality evidence of a survival benefit from platinum‐based regimens for women with mTNBC. This finding led us to conclude that "... although the evidence may be premature to recommend widespread use of platinum‐based regimens for mTNBC patients, some women and clinicians may consider platinum‐based regimens worth trying." We determined that there is a reasonable likelihood that this conclusion could change with the inclusion of additional studies; therefore we believe it is important to conduct a new review that updates the evidence from the mTNBC subgroup analyses in our previous Cochrane Review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013750-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013750-sec-0014"></div> <p>To assess the effects of platinum‐containing chemotherapy regimens with regimens not containing platinum in the management of women with mTNBC. </p> <p>Additional objectives of this review were to investigate whether or not women in selected subgroups of studies benefited more or less from platinum‐based chemotherapy. Subgroups analyses were pre‐specified in the protocol of our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), conducted in the original version of the review (<a href="./references#CD013750-bbs2-0035" title="CarrickS , GhersiD , WilckenN , SimesJ . Platinum containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub3]">Carrick 2004</a>) or added in response to new hypotheses and the availability of new subgroups. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013750-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013750-sec-0015"></div> <section id="CD013750-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013750-sec-0017"> <h4 class="title">Types of studies</h4> <p>Properly randomised controlled clinical trials (i.e. where the trial report asserts that the trial was randomised and there was no evidence to suggest otherwise) were eligible for inclusion. Because individual trials may compare one or more platinum‐based regimens to one or more non‐platinum‐based regimens, there were more 'treatment‐comparisons' (i.e. platinum regimen versus non‐platinum regimen comparisons) than studies in this review. </p> </section> <section id="CD013750-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants are women with mTNBC, whether newly diagnosed or recurrent, who may have been purposely selected for mTNBC, or inadvertently selected as a subgroup. Treatment‐comparisons that included groups of women with loco‐regionally recurrent disease or women with non‐TNBC were only eligible for inclusion if it was possible to distinguish between these groups (i.e. where data were reported separately) or if the proportion of women in each group represented at least 80% of the total group. There were no age restrictions.<br/><br/>In the protocol for the previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), it was proposed that studies would be included if the women randomised to receive chemotherapy were to receive it as first‐line treatment (i.e. if no previous chemotherapy were given except as adjuvant therapy). As few studies assessing first‐line treatment were identified for inclusion in the original version of the previous review, those meeting the remaining eligibility criteria but which involved participants who were not first‐line naive were included. This modification of the inclusion criteria was maintained for this review, with subgroup analysis by treatment being performed (treatment‐comparisons with first‐line therapy for &gt; 80% of participants versus other treatment lines). </p> </section> <section id="CD013750-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Interventions were any chemotherapy regimen containing a platinum agent (see <a href="#CD013750-tbl-0003">Table 1</a> and <a href="#CD013750-tbl-0004">Table 2</a>). Comparators were any chemotherapy regimen without a platinum agent. In the protocol for the previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), endocrine therapy could also have been given to participants if it had been planned to be given to both treatment groups. However, endocrine therapy is unlikely to be relevant to women with TNBC.<br/>Studies may or may not have specified recommended treatment upon disease progression or initial treatment failure, or both. This recommended treatment may have included cross‐over to the alternative treatment arm of the treatment‐comparison. </p> <div class="table" id="CD013750-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Common platinum agents</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Generic name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other names</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, Nealorin, Novoplatinum, Paraplat, Paraplatin AQ, Paraplatin, Paraplatine, Platinwas, Ribocarbo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abiplatin, Blastolem, Briplatin,CACP, CDDP, cis‐DDP, cis‐diamminedichloridoplatinum, cis‐diamminedichloro platinum (II), cis‐diamminedichloroplatinum, Cis‐dichloroammine Platinum (II), Cismaplat, Cisplatina, cis‐platinous diamine dichloride, cis‐platinum II diamine dichloride, cis‐platinum II, cis‐platinum, Cisplatyl, Citoplatino, Citosin, CPDD, Cysplatyna, DDP, DDP, Lederplatin, Metaplatin, Neoplatin, PDD, Peyrone's Chloride, Peyrone's Salt, Placis, Platamine, Platiblastin, Platiblastin‐S, Platinex, Platinol‐ AQ, Platinol, Platinol‐AQ VHA Plus, Platinol‐AQ, Platinoxan, platinum diamminodichloride, Platiran, Platistin, Platosin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ai Heng, Aiheng, diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum, oxaliplatine, Eloxatin, Dacotin, Dacplat, Eloxatine, 1‐OHP, L‐OHP, oxaliplatin medac </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013750-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of Agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Includes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agents that damage the DNA template</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrogen mustards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, melphalan, ifosfamide, chlorambucil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrosureas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>carmustine (BCNU), lomustine (CCNU)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: other agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thiotepa, mitomycin C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by platinum coordination cross‐linking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cisplatin, carboplatin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>doxorubicin, daunorubicin, mitoxantrone, idarubicin, epirubicin, amsacrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>podophyllotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>etoposide, teniposide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by intercalation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dactinomycin, mithramycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by uncertain mechanisms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bleomycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spindle poisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vinca alkaloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vincristine, vinblastine, vendesine, vinorelbine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxanes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxol, taxotere</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antimetabolites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thymidylate synthase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydrofolate reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013750-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013750-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013750-list-0001"> <li> <p>Overall survival (OS)</p> </li> <li> <p>Progression‐free survival/time to progression (PFS/TTP)</p> </li> </ul> </p> </section> <section id="CD013750-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013750-list-0002"> <li> <p>Time to treatment failure (TTF)</p> </li> <li> <p>Objective tumour response rate (OTRR)</p> </li> <li> <p>Toxicity rates (multiple condition‐specific outcomes)</p> </li> <li> <p>Quality of life (QoL) measures (multiple outcomes)</p> </li> </ul> </p> <p>The definitions of some outcomes varied slightly across studies included in this review. Outcomes were commonly defined as the following. </p> <p> <ul id="CD013750-list-0003"> <li> <p>OS: time elapsed between randomisation (or study enrolment or treatment initiation) to date of death from any cause. </p> </li> <li> <p>Progression‐free survival (PFS): time elapsed between randomisation (or study enrolment or treatment initiation) and event, with event defined as disease progression or death from any cause. </p> </li> <li> <p>Time to progression (TTP): time elapsed between randomisation (or study enrolment or treatment initiation) and event, with event defined as disease progression (which sometimes included cause‐specific death from the study disease). </p> </li> <li> <p>TTF: time elapsed between randomisation (or study enrolment or treatment initiation) to treatment discontinuation for any reason, including disease progression, treatment toxicity, participant preference, or death. </p> </li> <li> <p>OTRR: the proportion of participants who experienced a complete or partial tumour response (versus stable disease or no response). </p> </li> <li> <p>Toxicity rates (multiple condition‐specific outcomes): the proportions of participants who experienced a grade 3 or 4 adverse event of nausea and vomiting, nephrotoxicity, anaemia, hair loss and leukopaenia, based on WHO criteria or individual protocol‐based definitions. We also investigated treatment‐related death which, for the purpose of this review, was defined as death due to the toxicity of the drug and not to disease progression or other cause. If an individual trial did not include their definition of a treatment‐related death but used the terms "toxic death" or "lethal toxicity," then these deaths were counted as treatment‐related deaths. Lastly, in response to a reviewer suggestion, we also examined treatment discontinuation due to adverse events. </p> </li> <li> <p>QoL (generally measured using validated instruments for various QoL domains, but no studies in this review reported QoL results for mTNBC patients). </p> </li> </ul> </p> <p>For the purposes of this review, we analysed PFS and TTP as the same outcome (referred to as PFS/TTP), with preference given to PFS for studies reporting both PFS and TTP data. </p> </section> </section> </section> <section id="CD013750-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013750-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this review, we searched the following databases and registries on the 27 September 2019. </p> <p> <ul id="CD013750-list-0004"> <li> <p>The Cochrane Breast Cancer Specialised Register maintained by the Cochrane Breast Cancer Group (searched 2015 onwards). Details of the search strategies used by the Cochrane Breast Cancer Group for the identification of studies and the procedure used to code references are outlined in their module (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</a>). Trials coded with the key words 'advanced,' 'Cisplatin,' 'cisplatinum,' 'carboplatin,' 'carboplatinum,' 'platin,' 'platinum,' 'platinum diamminodichloride,' 'cis‐diamminedichloroplatinum,' 'cis‐dichlorodiammineplatinum,' 'biocisplatinum,' 'dichlorodiammineplatinum,' 'nsc‐119875,' 'platidiam,' 'platino,' 'Platinol,' 'cis‐diamminedichloroplatinum,' 'cis‐platinum,' 'cis‐diammine (cyclobutanedicarboxylato) platinum,' 'cbdca,' 'jm‐8,' 'nsc‐241240,' 'paraplatin' were extracted for consideration. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 9) in the Cochrane Library. See <a href="./appendices#CD013750-sec-0077">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (via OvidSP; from 2015 to 27 September 2019). See <a href="./appendices#CD013750-sec-0078">Appendix 2</a>. </p> </li> <li> <p>Embase (Via OvidSP; from 2015 to 27 September 2019). See <a href="./appendices#CD013750-sec-0079">Appendix 3</a>. </p> </li> <li> <p>The WHO International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">http://apps.who.int/trialsearch/Default.aspx</a>) for all prospectively registered and ongoing trials. See <a href="./appendices#CD013750-sec-0080">Appendix 4</a>. </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">http://clinicaltrials.gov/ct2/home</a>). See <a href="./appendices#CD013750-sec-0081">Appendix 5</a>. </p> </li> </ul> </p> <p>We applied no restrictions based on language.</p> </section> <section id="CD013750-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We obtained relevant studies published prior to 2015 and their extracted results from the mTNBC subgroup analysis in our previous Cochrane Review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>). We also searched for potentially relevant studies from previous trial reports, systematic reviews, and meta‐analyses. </p> </section> </section> <section id="CD013750-sec-0026"> <h3 class="title" id="CD013750-sec-0026">Data collection and analysis</h3> <section id="CD013750-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently applied the selection criteria (including the quality of randomisation) to each reference identified by the search strategy while masked to the study results. Any discrepancies regarding eligibility or quality were resolved by consensus or adjudication from a third review author. Studies that may appear to have met the eligibility criteria, but which were deemed ineligible, are listed in the <a href="./references#CD013750-sec-0092" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD013750-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Data on the relevant outcomes were extracted by at least two review authors, with discrepancies resolved by consensus or adjudication from another review author. Data were also extracted on information relating to outcome definitions, study accrual, randomisation methods, baseline characteristics of participants (e.g. age; first‐line or second‐line treatment; prior anthracyclines or anthracycline‐naive), chemotherapy regimens (number of cycles and duration), follow‐up time and analytical methods used. Where available, multiple publications on the same study were obtained and the most complete report was assigned as the primary reference. In instances where a more recent publication was used in this review for a study that was included in our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), the year of the reference ID was also updated. We entered data into the Cochrane Review Manager 5 (<a href="./references#CD013750-bbs2-0057" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) software, and we used this software for most statistical analyses. </p> </section> <section id="CD013750-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed potential sources of bias for all included studies, using the first version of Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD013750-bbs2-0049" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). At least two review authors independently evaluated the risk of bias for each treatment‐comparison and resolved discrepancies by consensus or adjudication from an additional reviewer. We sought clarification from authors if the published data provided inadequate information for the review. We assessed the 'Risk of bias' domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and 'other bias.' For each included study, we assigned ratings of 'high,' 'low,' or 'unclear' risk of bias for each 'Risk of bias' domain, following criteria outlined in the 'Risk of bias' assessment tool (<a href="./references#CD013750-bbs2-0049" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>Open‐label studies are common in phase III oncology trials because it is often difficult to conceal treatments from participants, care‐providers and outcome assessors (due to differences in toxicities and treatment schedules of various treatments, for example). However, because a lack of blinding can affect risk of bias in different ways for different outcomes, we assessed blinding of outcome assessment by dividing outcomes into two outcome classes: 1) OS and 2) outcomes other than OS and QoL. We made this division because, unlike other outcomes, assessment of OS is unlikely to be affected by non‐blinding. </p> <p>We also divided the 'incomplete outcome data' risk of bias domain into two outcome classes: 1) time‐to‐event outcomes and 2) binary (i.e. dichotomous) outcomes. For time‐to‐event outcomes, we deemed risk of bias to be low, unclear, and high risk if time‐to‐event analysis was intention‐to‐treat (ITT), modified intention‐to‐treat (mITT) or per‐protocol, respectively. For the binary outcomes (OTRRs and toxicity rates), risk of bias was deemed low, unclear, and high risk if the highest percentage of randomised participants excluded from effect estimation was less than 10%, between 10% and 15%, or more than 15%, respectively. </p> <p>For 'Risk of bias' domains that we divided into outcome classes, we made assessments for all studies known to be measuring the outcomes, regardless of results being reported in sufficient detail to be included in meta‐analysis or reported at all (e.g. a study might specify OS as an outcome in the study protocol but not report any results). </p> </section> <section id="CD013750-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed OS, PFS/TTP and TTF as time‐to‐event outcomes, for which the hazard ratio (HR) is the most appropriate measure of treatment effect. If reported, the HR and associated variance were extracted directly from the trial publication(s), and these were used to calculate observed (O) minus expected (E) numbers of events and logrank variance (V) for each treatment‐comparison using the methods described by <a href="./references#CD013750-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):1.">Tierney 2007</a> or <a href="./references#CD013750-bbs2-0056" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>. If not reported, we obtained O minus E and V indirectly from other available summary statistics or from data extracted from published Kaplan‐Meier curves using the methods described by <a href="./references#CD013750-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):1.">Tierney 2007</a> or <a href="./references#CD013750-bbs2-0056" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>. For studies that did not report the relevant effect estimates and required curve extraction, the numbers at risk were based on reported minimum and maximum follow‐up times. If these were not reported, minimum follow‐up was estimated as the time taken to complete treatment, and maximum follow‐up was estimated using the last event reported in the relevant time‐to‐event curve. These follow‐up estimates were recorded in the <a href="./references#CD013750-sec-0091" title="">Characteristics of included studies</a> table under 'Notes.' For the purposes of data extraction, we gave preference to time‐to‐event effect estimates derived from ITT analysis, followed by mITT analysis, then per‐protocol analysis. </p> <p>We obtained pooled HRs and 95% CIs from the O minus E and V statistics for each treatment‐comparison, using the fixed‐effect model (<a href="./references#CD013750-bbs2-0061" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases.1985;5:335-71.">Yusuf 1985</a>). The pooled HR represented the instantaneous risk of an event (such as death, disease progression or treatment failure) for women receiving platinum, divided by the corresponding risk for those not receiving platinum. HRs less than 1.00 favoured the platinum‐containing regimens and values greater than 1.00 favoured non‐platinum regimens. </p> <p>We analysed toxicity rates and OTRRs as proportions using the RR as the measure of treatment effect. OTRRs were most often calculated by trialists using only participants that were assessable for tumour response. These 'assessable participants' were generally defined as participants whose tumour response could be assessed according to prespecified criteria such as RECIST (<a href="./references#CD013750-bbs2-0040" title="EisenhauerE , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228-47.">Eisenhauer 2009</a>); this definition was sometimes extended to additionally exclude participants who had not received a specified minimum dose of chemotherapy. In this review, we calculated OTRRs using the numbers of assessable participants in the OTRR denominators, where available, and randomised participants in the OTRR denominators where assessable participants were not available. Toxicity rates were most often calculated by trialists using a 'safety population' of participants who received a specified minimum dose of chemotherapy. We calculated toxicity rates for each study using the population used by that study. </p> <p>We obtained pooled RRs and 95% CIs through Mantel‐Haenszel fixed‐effect analysis. The pooled RR represented the cumulative risk of an event for participants receiving platinum divided by the corresponding risk for those not receiving platinum. RRs greater than 1.00 favoured platinum‐containing regimens and values less than 1.00 favoured non‐platinum regimens. </p> <p>QoL is generally reported as a continuous outcome. Hence, if sufficient QoL data become available for meta‐analysis in future review updates, the effect measure would most likely be the mean difference (MD) or standardized mean difference (SMD), depending on whether the same or different validated questionnaires (respectively) were employed. The direction of QoL scales will be standardized across individual studies such MD and SMD values greater than zero will favour (i.e. better QoL) platinum‐containing regimens while values less than zero will favour non‐platinum regimens. To help with interpretation, we will re‐express SMDs in the original units of one of the QoL instruments. </p> </section> <section id="CD013750-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Treatment‐comparisons were the unit of analysis in this review and corresponded to pairwise comparisons of platinum and non‐platinum regimens. Individual studies assessing more than one platinum‐based regimen or more than one non‐platinum regimen (or both) contributed more than one treatment‐comparison to the review. Consequently, there were more treatment‐comparisons in this review than there were studies. </p> <p>One study contained two non‐platinum regimen (control) groups for comparison against a single platinum‐based regimen (intervention) group. We took this into account when we calculated treatment effect statistics by splitting the study into two treatment‐comparisons (<a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> and <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>) and halving the number of participants in the intervention group. For odd‐numbered group sizes, the additional participant was arbitrarily distributed to the treatment‐comparison with the label ending with 'A'. Two studies contained two platinum‐based regimen (intervention) groups for comparison against a single non‐platinum (control) group. These studies was split into two treatment‐comparisons (<a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a> and <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>) with treatment effect statistics calculated by halving the number of participants in the control group (with additional participants again arbitrarily distributed to treatment‐comparisons with label ending with 'A'). These methods for correcting for multiple intervention and/or control groups were suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013750-bbs2-0050" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane, July 2019.">Higgins 2019</a>). </p> </section> <section id="CD013750-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We made attempts to contact a number of trial investigators for additional information. One trialist (<a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>) provided additional results relating to their mTNBC subgroup. </p> </section> <section id="CD013750-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity (variation) between trial results was assessed using the Chi<sup>2</sup> test statistic and the I<sup>2</sup> statistic. The Chi<sup>2</sup> test statistic assesses the amount of variation in a set of trials. Small P values for the Chi<sup>2</sup> test statistic suggest that there is more heterogeneity present than would be expected by chance. Chi<sup>2</sup> is not a particularly sensitive test: a cut‐off of P value less than 0.10 is often used to indicate significance, but lack of statistical significance does not mean there is no heterogeneity. I<sup>2</sup> is the proportion of variation that is due to heterogeneity rather than chance. In conjunction with the Chi<sup>2</sup> test, we used the I<sup>2</sup> statistic to assess heterogeneity using the rule of thumb guide outlined in the Cochrane Handbook (<a href="./references#CD013750-bbs2-0050" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane, July 2019.">Higgins 2019</a>) (i.e. I<sup>2</sup> between 0% to 40% might not be important; between 30% to 60% may represent moderate heterogeneity; between 50% to 90% may represent substantial heterogeneity; and between 75% to 100% considerable heterogeneity). </p> </section> <section id="CD013750-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In addition to assessing each treatment‐comparison individually for selective outcome reporting, using the first version of Cochrane's 'Risk of bias' tool (see <a href="#CD013750-sec-0029">Assessment of risk of bias in included studies</a> above), we assessed publication bias and/or small‐study effects for the outcomes OS, PFS/TTP and OTRR by visual inspection of funnel plot asymmetry. We used Egger's statistical test to formally assess the degree of asymmetry (<a href="./references#CD013750-bbs2-0038" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). </p> </section> <section id="CD013750-sec-0035"> <h4 class="title">Data synthesis</h4> <p>For time‐to‐event outcomes, we used RevMan 5 (<a href="./references#CD013750-bbs2-0057" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) to estimate pooled HRs and 95% CIs, using fixed‐effect models of the derived or reported observed (O) and expected (E) number of events, and the variance of the log‐rank statistic (V) for each trial. For binary outcomes, we used RevMan 5 (<a href="./references#CD013750-bbs2-0057" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) to estimate pooled RRs and 95% CIs, using the fixed‐effect Mantel‐Haenszel method. </p> </section> <section id="CD013750-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses to determine whether the results differed by:</p> <p> <ol id="CD013750-list-0005"> <li> <p>type of regimen comparison: (a) regimen A + platinum versus regimen A, (b) regimen A + platinum versus regimen B, (c) single agent platinum versus regimen C; (note that we allowed 'regimen A' to differ in dosage by small amounts between intervention and control arms); </p> </li> <li> <p>type of platinum agent in platinum arm: (a) cisplatin, (b) carboplatin, (c) oxaliplatin;</p> </li> <li> <p>first‐line therapy: (a) first‐line therapy for &gt; 80% of participants, (b) second‐ or third‐line therapy for ≥ 20% of participants; </p> </li> <li> <p>taxane in regimens: (a) no taxane in platinum or non‐platinum regimens, (b) platinum + taxane versus non‐platinum + taxane regimens, (c) platinum + non‐taxane versus non‐platinum + taxane regimens, (d) platinum + taxane versus non‐platinum + non‐taxane regimens; </p> </li> <li> <p>BRCA1/2 mutation status: (a) germline BRCA1/2 mutation, (b) germline BRCA1/2 wild‐type; and </p> </li> <li> <p>homologous recombination deficiency status: (a) homologous recombination deficient, (b) not homologous recombination deficient. </p> </li> </ol> </p> <p>We assessed possible subgroup differences using Chi<sup>2</sup> tests. </p> <p>Of the above six subgroup analyses:</p> <p> <ul id="CD013750-list-0006"> <li> <p>subgroup analysis 1 was the only a priori subgroup analysis pre‐specified in the protocol of our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>); all other subgroup analyses were post hoc; </p> </li> <li> <p>subgroup analyses 2 to 4 were conducted in the original version (<a href="./references#CD013750-bbs2-0035" title="CarrickS , GhersiD , WilckenN , SimesJ . Platinum containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub3]">Carrick 2004</a>) of our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), and in our previous review; </p> </li> <li> <p>subgroup analysis 5 was added to the current review because three of the included trials (<a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>/<a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a><a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>, <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>) hypothesised that BRCA1/2 positive breast cancers may be sensitive to chemotherapy regimens containing platinum; and </p> </li> <li> <p>subgroup analysis 6 was added to the current review in response to hypotheses that somatic changes in tumours, similar to the effect of a germline BRCA mutation, could be predicted by HRD. </p> </li> </ul> </p> <p>In the original version (<a href="./references#CD013750-bbs2-0035" title="CarrickS , GhersiD , WilckenN , SimesJ . Platinum containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub3]">Carrick 2004</a>) of our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), and in our previous review, we assessed trastuzumab in regimens as a subgroup analysis. This analysis, however, was not included in the current review because trastuzumab is not a relevant treatment for women with TNBC. </p> <p>in order to reduce the number of forest plots in this review, toxicity rates were only shown overall and by subgroup analysis 2 ('type of platinum agent'). In general, however, few intervention‐comparisons could be included in meta‐analyses for adverse events. Better evidence of the toxicity of platinum regimens compared to non‐platinum regimens is found in our previous review's analysis of adverse events in women with metastatic breast cancer (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), regardless of mTNBC status. </p> <p>We had also intended to do a subgroup analysis looking at anthracycline in regimens. But because no studies had anthracycline in their platinum or non‐platinum regimens, the anthracycline subgroup meta‐analysis was not performed in this current version the review. </p> </section> <section id="CD013750-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed several sensitivity analyses. First, we performed sensitivity analyses to assess whether the absence of OS data from some studies included in this review may have affected the OS result. In these analyses, we subgrouped the pooled effect estimates for OTRR and PFS/TTP according to whether treatment‐comparisons were included in OS meta‐analysis. Second, we stratified PFS/TTP estimates according to whether the outcome was PFS or TTP. For these analyses, we classified estimates as PFS if the event of interest was defined as disease progression or death from any cause. We classified estimates as TTP if the event of interest was defined as disease progression, which may also include cause‐specific death from breast cancer. In instances where the event of interest was ambiguously defined or not defined at all, we relied on the authors label of the outcome for classifying as PFS or TTP. Third, to assess the sensitivity of our primary results to our choice of analytical method, we repeated the main analyses (<a href="./references#CD013750-fig-0009" title="">Analysis 1.1</a>, <a href="./references#CD013750-fig-0010" title="">Analysis 1.2</a> and <a href="./references#CD013750-fig-0011" title="">Analysis 1.3</a>) but using random‐effects rather than fixed‐effect methods. Fourth, it is plausible that trials not specifically assessing mTNBC patients might be more inclined to publish statistically significant mTNBC results from a subgroup analysis that was not pre‐specified in the trial protocol or trial registration. Consequently, we performed sensitivity analysis which subgrouped trials into those designed to specifically assess mTNBC patients and those where mTNBC patients were part of a post‐hoc subgroup analysis. Fifth, because <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> used a drug which is now widely considered to be ineffective in the treatment of breast cancer, the benefits of platinum chemotherapy are potentially exaggerated in the <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> trial. Therefore, we repeated the main analyses after exclusion of <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>. </p> </section> <section id="CD013750-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE system (<a href="./references#CD013750-bbs2-0047" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso-CoelloP , et al, the GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311-6.">Guyatt 2011</a>) to rate the quality of evidence relating to the estimated treatment effects on OS, PFS/TTP and OTRR, as well as on rates of treatment‐related death, nausea/vomiting, anaemia, hair loss, leukopaenia and treatment discontinuation due to adverse events. GRADE criteria for assessing quality of evidence include study design, risk of bias, inconsistency, indirectness, imprecision, suspected publication bias and other considerations. Assessments of these criteria and corresponding justifications are provided in three 'Summary of findings' tables, largely created using GRADEproGDT (<a href="./references#CD013750-bbs2-0044" title="GRADEproGDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.">GradeproGDT</a>). We performed GRADE assessments separately for selected subgroups related to inconsistency (i.e. heterogeneity) among effect estimates. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013750-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013750-sec-0039"></div> <section id="CD013750-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD013750-sec-0041"> <h4 class="title">Results of the search</h4> <p>We reviewed 1199 unique records identified by the 2019 database searches (<a href="#CD013750-fig-0001">Figure 1</a>). Of these, we excluded 1177 based on information in the title or abstract. We considered 11 records from trial registries or protocol publications to be potentially relevant. These were ongoing studies that have not yet published results (see <a href="./references#CD013750-sec-0093" title="">Characteristics of ongoing studies</a>). For the remaining 11 records, we retrieved full‐text articles or abstracts for further examination. We excluded five of the 11 articles or abstracts because they were review articles, but we examined their bibliographies to search for additional relevant studies. We excluded one other full‐text article for reasons outlined in the <a href="./references#CD013750-sec-0092" title="">Characteristics of excluded studies</a> table. We re‐assessed studies included in our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) for inclusion in the current review. </p> <div class="figure" id="CD013750-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review 2020: study flow diagram." data-id="CD013750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review 2020: study flow diagram.</p> </div> </div> </div> </section> <section id="CD013750-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 10 studies with 13 treatment‐comparisons in this review.</p> <p>Of these 13 treatment‐comparisons, eight were identified from our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>): three with the same mTNBC‐specific results reported in our previous review (<a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a>; <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a>) and five with new or updated mTNBC‐specific results (<a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>; <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>; <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>; <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). The other five treatment‐comparisons were identified by our September 2019 search (<a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>). </p> <p>Of the 13 treatment‐comparisons included in this review (<a href="#CD013750-tbl-0005">Table 3</a>): </p> <div class="table" id="CD013750-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons by subgroup and three outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Treatment‐</b> </p> <p><b>comparisons</b> </p> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Overall</b> </p> <p><b>survival</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Progression</b> </p> <p><b>‐free</b> </p> <p><b>survival/time to</b> </p> <p><b>progression</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Objective</b> </p> <p><b>tumour</b> </p> <p><b>response</b> </p> <p><b>rate</b> </p> <p><b>n (% of N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Overall:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (46%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8 (62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10 (77%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Type of regimen comparison:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Regimen A + platinum agent vs regimen A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Regimen A + platinum agent vs regimen B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (44%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7 (78%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Single agent platinum vs regimen C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Type of platinum agent in platinum arm:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cisplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (29%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (29%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Carboplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (67%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>First‐line therapy:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>First‐line therapy for &gt; 80% of patients</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Second‐ or third‐line therapy for &gt;=20% of patients</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (14%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (43%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (57%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Anthracycline in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (46%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8 (62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10 (77%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Taxane in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No taxane in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (80%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum + taxane vs non‐platinum + non‐taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>BRCA1/2 subtype:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Germline BRCA1/2 mutation #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germline BRCA1/2 wild‐type #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Homologous recombination deficiency status:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homologous recombination deficient #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not homologous recombination deficient #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>^Numbers for each outcome are the number of treatment‐comparison with sufficient data to be included in meta‐analysis for that outcome. </p> <p># BRCA1/2 subtype and homologous recombination deficiency status were within‐study subgroupings for <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> and <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>; hence <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> and <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> both contributed to both BRCA1/2 subroups and both homologous recombination deficiency status subgroups. </p> </div> </div> <p> <ul id="CD013750-list-0007"> <li> <p>two (15%) compared 'regimen A + platinum versus regimen A,' nine (69%) compared 'regimen A + platinum versus regimen B' and 2 (15%) compared single agent platinum versus regimen C' (<a href="#CD013750-tbl-0005">Table 3</a>); </p> </li> <li> <p>seven (54%) used cisplatin and 6 (46%) used carboplatin as the platinum agent in the intervention arm (<a href="#CD013750-tbl-0005">Table 3</a> and <a href="#CD013750-tbl-0006">Table 4</a>); </p> </li> <li> <p>six (46%) had more than 80% of participants receiving first‐line therapy;</p> </li> <li> <p>all 13 (100%) had no anthracycline in the platinum or non‐platinum regimens (consequently, the anthracycline subgroup meta‐analysis was not performed); </p> </li> <li> <p>four (31%) had no taxane in the platinum or non‐platinum regimens; two (15%) had a taxane in both regimens, five (38%) had a taxane in the non‐platinum regimen only and two (15%) had a taxane in the platinum regimen only; </p> </li> <li> <p>four (31%) had germline BRCA1/2 mutation subgroup results and two (13%) had BRCA1/2 wild‐type subgroup results; and </p> </li> <li> <p>two (15%) were homologous recombination deficient and two (15%) were not homologous recombination deficient. </p> </li> </ul> </p> <div class="table" id="CD013750-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trials ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 1</b> <b>(platinum‐containing)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 2</b> <b>(control)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line therapy for &gt; 80% of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Majority participants anthracycline‐naive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Endoxan + with 'cisplatinum')</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Endoxan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C + Cb (Cetuximab + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (Cetuximab with carboplatin added after progression)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (docetaxel + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TX (docetaxel + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCP (placebo + carboplatin/paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VT (veliparib + temozolomide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCP (eliparib + carboplatin/paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VT (veliparib + temozolomide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemVin (gemcitabine + vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCap (gemcitabine + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/C (nab‐paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/G (nab‐paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G/C (gemcitabine + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/G (nab‐paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D (docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> </table> </div> <p>Not all studies provided sufficient information on all outcomes for inclusion in meta‐analyses. Of the 13 treatment‐comparisons: </p> <p> <ul id="CD013750-list-0008"> <li> <p>six (46%), eight (62%) and 10 (77%) had sufficient data to be included in the meta‐analyses of effect estimates for OS, PFS/TTP and OTRR, respectively (<a href="#CD013750-tbl-0005">Table 3</a> and <a href="#CD013750-fig-0001">Figure 1</a>); and </p> </li> <li> <p>five (38%), three (23%), zero (0%), five (38%), two (15%), five (38%) and five (38%) had sufficient data to be included in the meta‐analyses of effect estimates for treatment‐related death, nausea/vomiting, nephrotoxicity, anaemia, hair loss, leukopaenia, and treatment discontinuation due to adverse events, respectively (<a href="#CD013750-tbl-0007">Table 5</a> and <a href="#CD013750-fig-0001">Figure 1</a>). </p> </li> </ul> </p> <div class="table" id="CD013750-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS data useable for HR estimation for mTNBC patients<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> <b>OS time for mTNBC patients<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PFS/TTP data useable for HR estimation for mTNBC patients<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median PFS/TTP time for mTNBC patients<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective tumour response for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related deaths for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade III &amp; IV Toxicity for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not useable for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not useable for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopaenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Sufficient data reported to estimate a HR for pooling as outlined by <a href="./references#CD013750-bbs2-0056" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a> and <a href="./references#CD013750-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):1.">Tierney 2007</a>; this includes Kaplan‐Meier curve, HR and standard error/confidence interval or logrank statistics<br/><sup>2</sup>Trials that did not explicitly report median time were classified as NR here regardless of estimable median time from Kaplan‐Meier curve<br/><sup>3</sup>Analysed numbers represent the maximum numbers of participants in the treatment‐comparison that were included in a meta‐analysis of OS, PFS/TTP or OTRR (assessable participants). </p> <p>DU: deaths unexplained<br/>NR: not reported at all or not reported for mTNBC subgroup<br/>OS: overall survival<br/>PFS: progression‐free survival<br/>TTP: time to progression<br/>Y: year reported </p> </div> </div> <p>No studies reported QoL or TTF results for women with mTNBC.</p> </section> <section id="CD013750-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Eight studies may have appeared to have met the eligibility criteria but were deemed ineligible for reasons given in the <a href="./references#CD013750-sec-0092" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD013750-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD013750-fig-0002">Figure 2</a> shows a summary of the 'Risk of bias' judgements for each 'Risk of bias' domain of the included treatment‐comparisons. Reasons for each judgement are detailed for each treatment‐comparison in the <a href="./references#CD013750-sec-0091" title="">Characteristics of included studies</a> table. For each 'Risk of bias' domain, a summary of the general risk of bias for results of the included studies was as follows. </p> <div class="figure" id="CD013750-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013750-sec-0045"> <h4 class="title">Allocation</h4> <p>All 10 studies, reporting 13 treatment‐comparisons, were described as randomised. The method of random sequence generation was described sufficiently to be judged at low risk of bias for this domain in six treatment‐comparisons (<a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a>; <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). The remaining seven treatment‐comparisons were judged to be at unclear risk of bias for random sequence generation, as the information available was insufficient to accurately assess this domain. </p> <p>Five of the 13 treatment‐comparisons described central randomisation systems, and were thus judged to be at low risk of bias for treatment allocation concealment (<a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>; <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). The remaining seven treatment‐comparisons did not adequately describe methods of concealment and were thus judged as having unclear risk of bias for this domain. </p> </section> <section id="CD013750-sec-0046"> <h4 class="title">Blinding</h4> <p>Eleven treatment‐comparisons were described as "nonblinded," "not blinded," "single blind" or "open‐label" (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a>; <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>; <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>; <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>; <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). These 11 'unblinded' treatment‐comparisons were judged to be at high risk of 'performance bias' due to the lack of blinding of participants and personnel to the treatment being administered. The remaining two treatment‐comparisons were judged as at unclear risk of performance bias because of a lack of information needed to make a firm conclusion. It seemed highly likely, however, that these two treatment‐comparisons would have also been 'unblinded,' as open‐label studies are common in phase III oncology trials. </p> <p>All 12 treatment‐comparisons known to have OS as a study outcome (including six not included in OS meta‐analyses; but excluding <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a>, which did not assess OS as an outcome) were judged to be at low risk of bias from a lack of blinding of outcome assessors, regardless of actual blinding. This is because death certification was unlikely to have been affected by any lack of blinding. </p> <p>For outcomes other than OS and QoL, two treatment‐comparisons were judged to be at low risk of bias from a lack of blinding of outcome assessors due to these outcomes being measured or confirmed through formal assessments including imaging, biochemical tests and/or the involvement of an independent clinical or radiological review group (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>). Three treatment‐comparisons were judged to be at high risk of bias from a lack of blinding of outcome assessors (<a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>). The remaining eight treatment‐comparisons provided insufficient detail on outcome assessments and were thus classified as having an unclear risk of bias. </p> </section> <section id="CD013750-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Five treatment‐comparisons excluded randomised participants who never started treatment or who were subsequently found to have been 'ineligible' from time‐to‐event analyses (mITT analyses) (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). These five treatment‐comparisons were judged to be at unclear risk of attrition bias for time‐to‐event outcomes. The remaining eight treatment‐comparisons were judged to be at low risk of attrition bias for time‐to‐event outcomes because all randomised participants were analysed in the groups to which they were randomised (ITT analysis). </p> <p>Two treatment‐comparisons had more than 15% of participants not assessed or not assessable for at least one binary outcome, and were thus judged to be at high risk of attrition bias for binary outcomes (<a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>; <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>). Five treatment‐comparisons had less than 10% of participants not assessed or not assessable for all binary outcomes, and were thus judged to be at low risk of attrition bias for binary outcomes (<a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a>; <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). The remaining six treatment‐comparisons were judged to be at unclear risk of attrition bias for binary outcomes (10% to 15% of participants not assessed or not assessable for at least one binary outcome, or it was unclear what proportion were not assessed). </p> </section> <section id="CD013750-sec-0048"> <h4 class="title">Selective reporting</h4> <p>The assessment of risk of bias from selective reporting included cross‐checking the outcomes for which there were published results against the stated outcomes reported in trial registers and published protocols. In our assessment of risk of bias from selective reporting, studies that began recruiting participants on or after July 1, 2005 were expected have a clinical registration or published protocol specifying the study outcomes, or we deemed them to be at high risk of bias from selective reporting. We chose July 1, 2005 as our early limit because the International Committee of Medical Journal Editors (ICMJE) made a seminal announcement in September 2004 that clinical trials that begin recruiting on or after July 1, 2005 would not be considered for publication unless they were included on a clinical trials registry (<a href="./references#CD013750-bbs2-0037" title="De AngelisCD , DrazenJM , FrizelleFA , HaugC , HoeyJ , HortonR , et al. Is this clinical trial fully registered?—A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine2005;352(23):2436-8.">De Angelis 2005</a>). Studies included in this review that began recruiting participants before July 1, 2005 and which did not have a trial registration or published protocol pre‐specifying study outcomes, were assumed to be at unclear risk of bias from selective reporting, unless additional evidence suggested otherwise. </p> <p>Four treatment‐comparisons from three studies were judged to be at low risk of bias from the selective reporting of outcomes (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>). Each of these studies was included on a clinical trials registry and their prespecified outcomes either matched those in the trial reports or non‐matches were considered to be relatively minor. Eight treatment‐comparisons were judged to be at high risk of bias from the selective reporting of outcomes. Of these eight treatment‐comparisons: <a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a> indicated in the abstract that toxicity was recorded, but did not report results; there was no trial registration or published protocol containing the study's prespecified outcomes). <a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a> and <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a> did not have a trial registration or published protocol, despite recruitment beginning after July 1, 2005. <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>/<a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>, <a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a> and <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>/<a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> did not report all outcomes specified in their protocol for the mTNBC subgroup analysis. We judged the remaining treatment‐comparison (<a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>) to be at unclear risk of bias from the selective reporting of outcomes because while the protocol‐specified outcomes of TTP and TTF were not reported, the similar outcome of PFS was reported. </p> <p>Egger's tests for funnel plot asymmetry indicated some evidence consistent with the presence of publication bias or small‐study effects, or both, for PFS/TTP (P = 0.02; <a href="#CD013750-fig-0003">Figure 3</a>) but not for OS (P = 0.08; <a href="#CD013750-fig-0004">Figure 4</a>) or OTRR (P = 0.12; <a href="#CD013750-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD013750-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot for PFS/TTP (Progression‐free survival/time to progression). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for PFS/TTP that could be included in meta‐analysis. The plot suggests some level of asymmetry (Egger's test P value = 0.02)." data-id="CD013750-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for PFS/TTP (Progression‐free survival/time to progression). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for PFS/TTP that could be included in meta‐analysis. The plot suggests some level of asymmetry (Egger's test P value = 0.02). </p> </div> </div> </div> <div class="figure" id="CD013750-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OS that could be included in meta‐analysis.. The plot does not show substantial asymmetry (Egger's test P value = 0.08)" data-id="CD013750-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OS that could be included in meta‐analysis.. The plot does not show substantial asymmetry (Egger's test P value = 0.08) </p> </div> </div> </div> <div class="figure" id="CD013750-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot for objective tumour response rate (OTRR). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OTRR that could be included in meta‐analysis. The plot does not show asymmetry (Egger's test P value = 0.12)." data-id="CD013750-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for objective tumour response rate (OTRR). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OTRR that could be included in meta‐analysis. The plot does not show asymmetry (Egger's test P value = 0.12). </p> </div> </div> </div> </section> <section id="CD013750-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>Eight treatment‐comparisons were judged to be at unclear risk of 'other bias' (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a>; <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>; <a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a>; <a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a>; <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>) for various reasons outlined in the <a href="./references#CD013750-sec-0091" title="">Characteristics of included studies</a> table. The remaining five treatment‐comparisons were judged to be at low risk of 'other bias.' </p> </section> </section> <section id="CD013750-sec-0050"> <h3 class="title" id="CD013750-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD013750-tbl-0001"><b>Summary of findings 1</b> Platinum compared to non‐platinum regimens for metastatic triple‐negative breast cancer: OS, PFS/TTP and OTRR</a>; <a href="./full#CD013750-tbl-0002"><b>Summary of findings 2</b> Platinum‐containing regimens and toxicity profile</a> </p> <p>Please refer to <a href="./full#CD013750-tbl-0001">summary of findings Table 1</a> </p> <section id="CD013750-sec-0051"> <h4 class="title">Overall survival</h4> <p>Twelve of the 13 included treatment‐comparisons assessed OS as an outcome; six provided sufficient OS data specific to mTNBC patients for pooling in meta‐analyses. From these six treatment‐comparisons, 958 of 972 randomised participants were analysed representing 99% of randomised participants in these treatment‐comparisons (and there were about 573 deaths). Pooled analysis indicated a 15% lower rate of death for women receiving platinum‐containing regimens compared to those receiving non‐platinum regimens (HR 0.85, 95% CI 0.73 to 1.00; P = 0.05; heterogeneity P = 0.41, I<sup>2</sup> = 1%; moderate‐quality evidence) (<a href="./references#CD013750-fig-0009" title="">Analysis 1.1</a>; <a href="#CD013750-fig-0006">Figure 6</a>). Subgroup analyses of OS indicated no evidence of subgroup differences (P values ranged from P = 0.19 to P = 0.89; see <a href="./references#CD013750-fig-0012" title="">Analysis 2.1</a>; <a href="./references#CD013750-fig-0015" title="">Analysis 3.1</a>; <a href="./references#CD013750-fig-0024" title="">Analysis 4.1</a>; <a href="./references#CD013750-fig-0027" title="">Analysis 5.1</a>; <a href="./references#CD013750-fig-0030" title="">Analysis 6.1</a>; <a href="./references#CD013750-fig-0033" title="">Analysis 7.1</a>). </p> <div class="figure" id="CD013750-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.1 Overall survival." data-id="CD013750-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.1 Overall survival. </p> </div> </div> </div> </section> <section id="CD013750-sec-0052"> <h4 class="title">PFS/TTP</h4> <p>All 13 included treatment‐comparisons assessed PFS or TTP, or both, as an outcome; eight provided sufficient mTNBC‐specific data for pooling in meta‐analyses of the composite outcome of PFS/TTP. From these eight treatment‐comparisons, 1077 out of 1092 (99%) randomised participants were analysed (with approximately 909 events). Pooled analysis indicated platinum‐containing regimens were associated with better PFS/TTP (HR 0.77, 95% CI 0.68 to 0.88; P &lt; 0.0001), although the quality of the evidence was very low. This was due to marked evidence of heterogeneity (P &lt; 0.0001; I<sup>2</sup> = 80%) (<a href="./references#CD013750-fig-0010" title="">Analysis 1.2</a>; <a href="#CD013750-fig-0007">Figure 7</a>), the use of PFS/TTP is a surrogate endpoint and suspected publication bias (<a href="./full#CD013750-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD013750-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.2 Progression‐free survival/time to progression." data-id="CD013750-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.2 Progression‐free survival/time to progression. </p> </div> </div> </div> <p>Evidence of subgroup differences in the pooled HRs of subgroups was found in four of the six subgroup analyses involving PFS/TTP: </p> <p> <ul id="CD013750-list-0009"> <li> <p>comparing 'regimen A + platinum versus regimen A' (HR 0.56, 95% CI 0.41 to 0.77; n = 1); 'regimen A + platinum versus regimen B' (HR 0.68, 95% CI 0.55 to 0.82; heterogeneity P = 0.007, I<sup>2</sup> = 71%; n = 5); and 'single agent platinum versus regimen C' (HR 1.00, 95% CI 0.83 to 1.22; heterogeneity P = 0.004, I<sup>2</sup> = 88%; n = 2) (P = 0.002 for subgroup difference) (<a href="./references#CD013750-fig-0013" title="">Analysis 2.2</a>); </p> </li> <li> <p>comparing first‐line therapy for &gt; 80% of participants (HR 0.89, 95% CI 0.77 to 1.04; heterogeneity P = 0.002, I<sup>2</sup> = 77%; n = 5); and second‐ or third‐line therapy for ≥ 20% of participants (HR 0.50, 95% CI 0.38 to 0.64; heterogeneity P = 0.32, I<sup>2</sup> = 13%; n = 3) (P &lt; 0.0001 for subgroup difference) (<a href="./references#CD013750-fig-0025" title="">Analysis 4.2</a>); </p> </li> <li> <p>with no taxane in platinum or non‐platinum regimens (HR 0.56, 95% CI 0.41to 0.77; n = 1); a taxane in both the platinum and non‐platinum regimens (HR 0.46, 95% CI 0.30 to 0.70; heterogeneity P = 0.11, I<sup>2</sup> = 61%; n = 2); a taxane in the non‐platinum regimen only (HR 0.98, 95% CI 0.84 to 1.15; heterogeneity P = 0.17, I<sup>2</sup> = 43%; n = 3); and a taxane in the platinum regimen only (HR 0.37, 95% CI 0.23 to 0.59; heterogeneity P = 0.67, I<sup>2</sup> = 0%; n = 2) (P &lt; 0.00001 for subgroup difference) (<a href="./references#CD013750-fig-0028" title="">Analysis 5.2</a>); </p> </li> <li> <p>with women with germline BRCA 1/2 mutation (HR 0.43, 95% CI 0.30 to 0.62; heterogeneity P = 0.73, I<sup>2</sup> = 0%; n = 4); compared to women with germline BRCA 1/2 wild‐type (HR 1.14, 95% CI 0.93 to 1.40; heterogeneity P = 0.18, I<sup>2</sup> = 45%; n = 2). (P &lt; 0.00001 for subgroup difference) (<a href="./references#CD013750-fig-0031" title="">Analysis 6.2</a>). </p> </li> </ul> </p> <p>The two other subgroup analyses showed no evidence of subgroup differences (P values ranged from P = 0.14 to P = 0.75; see <a href="./references#CD013750-fig-0016" title="">Analysis 3.2</a>; <a href="./references#CD013750-fig-0034" title="">Analysis 7.2</a>). </p> </section> <section id="CD013750-sec-0053"> <h4 class="title">TTF</h4> <p>None of the 13 included treatment‐comparisons assessed TTF as an outcome.</p> </section> <section id="CD013750-sec-0054"> <h4 class="title">OTRR: assessable participants</h4> <p>All 13 included treatment‐comparisons assessed OTRR as an outcome; 10 provided sufficient OTRR data specific to mTNBC patients for pooling in meta‐analyses. From the 10 treatment‐comparisons, 1205 out of 1244 (97%) randomised participants were assessable for tumour response (and 529 had a complete or partial response). Women receiving platinum‐containing regimens had 40% better OTRR than women receiving non‐platinum regimens (RR 1.40, 95% CI 1.22 to 1.59, P &lt; 0.00001), but the quality of the evidence was low because of evidence of heterogeneity (P = 0.01; I<sup>2</sup> = 58%) (<a href="./references#CD013750-fig-0011" title="">Analysis 1.3</a>; <a href="#CD013750-fig-0008">Figure 8</a>) and because OTRR is a surrogate endpoint (<a href="./full#CD013750-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD013750-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.3 Objective tumour response rate (assessable participants)." data-id="CD013750-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.3 Objective tumour response rate (assessable participants). </p> </div> </div> </div> <p>Evidence of subgroup differences in the pooled RRs of subgroups were found in five of the six OTRR subgroup analyses: </p> <p> <ul id="CD013750-list-0010"> <li> <p>comparing 'regimen A + platinum versus regimen A' (RR 2.14, 95% CI 1.42 to 3.23; heterogeneity P = 0.64, I<sup>2</sup> = 0%; n = 2); 'regimen A + platinum versus regimen B' (RR 1.51, 95% CI 1.29 to 1.77; heterogeneity P = 0.14, I<sup>2</sup> = 38%; n = 7); and 'single agent platinum versus regimen C' (RR 0.92, 95% CI 0.69 to 1.23; n = 1) (P = 0.003 for subgroup difference) (<a href="./references#CD013750-fig-0014" title="">Analysis 2.3</a>); </p> </li> <li> <p>using cisplatin (RR 1.61, 95% CI 1.36 to 1.89; heterogeneity P = 0.05, I<sup>2</sup> = 54%; n = 6); and carboplatin (RR 1.16, 95% CI 0.93 to 1.44; heterogeneity P = 0.06, I<sup>2</sup> = 59%; n = 4) (P = 0.02 for subgroup difference) (<a href="./references#CD013750-fig-0017" title="">Analysis 3.3</a>); </p> </li> <li> <p>comparing first‐line therapy for &gt; 80% of participants (RR 1.30, 95% CI 1.13 to 1.50; heterogeneity P = 0.02, I<sup>2</sup> = 63%; n = 6); and second‐ or third‐line therapy for ≥ 20% of participants (RR 2.05, 95% CI 1.42 to 2.96; heterogeneity P = 0.25, I<sup>2</sup> = 27%; n = 4) (P = 0.02 for subgroup difference) (<a href="./references#CD013750-fig-0026" title="">Analysis 4.3</a>); </p> </li> <li> <p>with no taxane in the platinum or non‐platinum regimens (RR 2.05, 95% CI 1.42 to 2.96; heterogeneity P = 0.25, I<sup>2</sup> = 27%; n = 4); a taxane in both platinum and non‐platinum regimens (RR 2.23, 95% CI 1.48 to 3.38; heterogeneity P = 0.11, I<sup>2</sup> = 61%; n = 2); a taxane in the non‐platinum regimen only (RR 1.18, 95% CI 1.02 to 1.38; heterogeneity P = 0.13, I<sup>2</sup> = 47%; n = 4) (P = 0.001 for subgroup difference) (<a href="./references#CD013750-fig-0029" title="">Analysis 5.3</a>); </p> </li> <li> <p>with women with germline BRCA 1/2 mutation (RR 2.09, 95% CI 1.17 to 3.72; heterogeneity P = 0.89, I<sup>2</sup> = 0%; n = 2); compared to women with germline BRCA 1/2 wild‐type (RR 0.90, 95% CI 0.71 to 1.15; heterogeneity P = 0.05, I<sup>2</sup> = 74%; n = 2) (P = 0.008 for subgroup difference) (<a href="./references#CD013750-fig-0032" title="">Analysis 6.3</a>). </p> </li> </ul> </p> <p>The other subgroup analyses showed no evidence of subgroup differences (P = 0.30 for <a href="./references#CD013750-fig-0035" title="">Analysis 7.3</a>). </p> </section> <section id="CD013750-sec-0055"> <h4 class="title"><i>Toxicity: safety populations</i> </h4> <p>Please refer to <a href="./full#CD013750-tbl-0002">summary of findings Table 2</a> </p> <section id="CD013750-sec-0056"> <h5 class="title"><i>Treatment‐related death</i> </h5> <p>Five of the 13 included treatment‐comparisons reported treatment‐related death for mTNBC patients and provided sufficient data for extraction. Of these five treatment‐comparisons, two had non‐estimable RRs due to no treatment‐related deaths and thus did not contribute to the pooled estimates. For the three remaining treatment‐comparisons, 554 out of 567 (98%) randomised women were included in the safety populations, with six treatment‐related deaths. There was no evidence of a difference between platinum and non‐platinum regimens in terms of treatment‐related death but the quality of evidence was low because the confidence interval was very wide (RR 1.06, 95% CI 0.24 to 4.61; <a href="./references#CD013750-fig-0018" title="">Analysis 3.4</a>) (<a href="./full#CD013750-tbl-0002">summary of findings Table 2</a>). There was no evidence of heterogeneity (P = 0.69; I<sup>2</sup> = 0%). </p> <p>It was not possible to perform subgroup analyses according to the type of platinum agent used, as the two cisplatin treatment‐comparisons had non‐estimable RRs, due to no treatment‐related deaths. </p> </section> <section id="CD013750-sec-0057"> <h5 class="title"><i>Nausea/vomiting</i> </h5> <p>Three of the 13 included treatment‐comparisons reported grade 3 and 4 nausea/vomiting for mTNBC patients with sufficient data for extraction. Of these three treatment‐comparisons, 655 out of 669 (98%) randomised women were included in the safety populations with 31 cases of grade 3 or 4 nausea/vomiting. Risk of grade 3 or 4 nausea/vomiting was nearly five times higher among women receiving platinum‐containing regimens (RR 4.77, 95% CI 1.93 to 11.81; P = 0.0007) but the quality of evidence was deemed low because the confidence interval was very wide. There was no evidence of heterogeneity (P = 0.32, I<sup>2</sup> = 12%) (<a href="./references#CD013750-fig-0019" title="">Analysis 3.5</a>). </p> <p>There was little evidence of difference in pooled RRs according to the type of platinum agent used (P = 0.15). </p> </section> <section id="CD013750-sec-0058"> <h5 class="title"><i>Nephrotoxicity</i> </h5> <p>None of the 13 included treatment‐comparisons reported grade 3 and 4 nephrotoxicity for mTNBC patients. </p> </section> <section id="CD013750-sec-0059"> <h5 class="title"><i>Anaemia</i> </h5> <p>Five of the 13 included treatment‐comparisons reported grade 3 and 4 anaemia in mTNBC patients and provided sufficient data for extraction. Of these five treatment‐comparisons, one had a non‐estimable RR due to no grade 3 and 4 anaemia and thus did not contribute to the pooled estimates. For the three remaining treatment‐comparisons, 790 out of 807 (98%) randomised women were included in the safety populations, with 86 cases of grade 3 and 4 anaemia. Risk of grade 3 or 4 anaemia was nearly four times higher among women receiving platinum‐containing regimens (RR 3.80, 95% CI 2.25 to 6.42; P &lt; 0.00001) (<a href="./references#CD013750-fig-0020" title="">Analysis 3.6</a>), but the quality of evidence was deemed low because the confidence interval was wide and there was some evidence of heterogeneity (P = 0.04; I<sup>2</sup> = 65%). </p> <p>Subgroup analysis showed weak evidence indicating that the increased risk of grade 3 or 4 anaemia for platinum recipients (compared to non‐platinum recipients) was worse for cisplatin recipients compared to carboplatin recipients (P = 0.06). </p> </section> <section id="CD013750-sec-0060"> <h5 class="title"><i>Hair loss</i> </h5> <p>Two of the 13 included treatment‐comparisons assessed grade 3 and 4 hair loss for mTNBC patients and reported sufficient data for extraction. One of these two treatment‐comparisons had a non‐estimable RR due to there being no grade 3 or 4 cases. For the one remaining treatment‐comparison, 366 out of 376 (97%) randomised women were included in the safety population, with one case of grade 3 or 4 hair loss. There was no evidence that the risk of grade 3 or 4 hair loss was different for women receiving platinum‐containing regimens (RR 0.33, 95% CI 0.01 to 8.04) (<a href="./references#CD013750-fig-0021" title="">Analysis 3.7</a>), but the quality of evidence was low because the confidence interval was very wide. </p> </section> <section id="CD013750-sec-0061"> <h5 class="title"><i>Leukopaenia</i> </h5> <p>Five of the 13 included treatment‐comparisons assessed grade 3 and 4 leukopaenia for mTNBC patients and reported sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no grade 3 or 4 cases of leukopaenia. For the four remaining treatment‐comparisons, 790 out of 807 (98%) randomised women were included in the safety populations, with 131 cases of grade 3 or 4 leukopaenia. There was no evidence of a difference in risk of grade 3 or 4 leukopaenia between platinum and non‐platinum containing regimens (RR 1.09, 95% CI 0.84 to 1.42, P = 0.52). The quality of evidence was deemed moderate because the confidence interval was wide. There was no evidence of heterogeneity (P = 0.75, I<sup>2</sup> = 0%) (<a href="./references#CD013750-fig-0022" title="">Analysis 3.8</a>). </p> <p>There was no evidence of differences in pooled RRs according to the type of platinum agent used (P = 0.44). </p> </section> <section id="CD013750-sec-0062"> <h5 class="title"><i>Treatment discontinuation due to adverse events</i> </h5> <p>Five of the 13 included treatment‐comparisons assessed treatment discontinuation due to adverse events and reported sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no treatment discontinuations. For the four remaining treatment‐comparisons, 790 out of 807 (98%) randomised women were included in the safety populations, with 89 treatment discontinuations. There was no evidence of a difference in risk of treatment discontinuations between platinum and non‐platinum containing regimens (RR 0.88, 95% CI 0.59 to 1.32, P = 0.55). The quality of evidence was deemed moderate because the confidence interval was wide. There was some evidence of heterogeneity (P = 0.07, I<sup>2</sup> = 57%) (<a href="./references#CD013750-fig-0023" title="">Analysis 3.9</a>). </p> <p>There was no evidence of differences in pooled RRs according to the type of platinum agent used (P = 0.63). </p> </section> </section> <section id="CD013750-sec-0063"> <h4 class="title">QoL</h4> <p>None of the 13 included treatment‐comparisons reported QoL outcomes for mTNBC patients.</p> </section> <section id="CD013750-sec-0064"> <h4 class="title"><i>Sensitivity analyses</i> </h4> <p> <ul id="CD013750-list-0011"> <li> <p>The benefit of platinum regimens over non‐platinum regimens in terms of PFS/TTP was more pronounced for treatment‐comparisons not included in the OS meta‐analysis (HR 0.37, 95% CI 0.23 to 0.59; n = 2) than for treatment‐comparisons included the OS meta‐analysis (HR 0.82, 95% CI 0.72 to 0.94; n = 6) (P = 0.001 for subgroup difference) (<a href="./references#CD013750-fig-0036" title="">Analysis 8.1</a>). Similarly, the benefit of platinum regimens over non‐platinum regimens in terms of OTRR was marginally more pronounced for treatment‐comparisons not included in the OS meta‐analysis (RR 1.70, 95% CI 1.33 to 2.18; n = 4) than for treatment‐comparisons included the OS meta‐analysis (RR 1.30, 95% CI 1.11 to 1.52; n = 6) (P = 0.07 for subgroup difference) (<a href="./references#CD013750-fig-0037" title="">Analysis 8.2</a>). Together these results provide some suggestion that the absence of some treatment‐comparisons (namely <a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a>; <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a>; <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>; <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>) from the OS meta‐analysis may have, if anything, lead to an underestimate of the benefit of platinum regimens in terms of OS. </p> </li> <li> <p>Stratifying PFS/TTP estimates according to whether the outcome was PFS or TTP suggested that platinum chemotherapy was more beneficial in terms of TTP than PFS (P = 0.03), although this difference was based on only one treatment‐comparison in the TTP group (<a href="./references#CD013750-fig-0038" title="">Analysis 9.1</a>). </p> </li> <li> <p>Repeating <a href="./references#CD013750-fig-0009" title="">Analysis 1.1</a>, <a href="./references#CD013750-fig-0010" title="">Analysis 1.2</a> and <a href="./references#CD013750-fig-0011" title="">Analysis 1.3</a> using random‐effects methods did not appreciably change the pooled estimates (<a href="./references#CD013750-fig-0039" title="">Analysis 10.1</a>; <a href="./references#CD013750-fig-0040" title="">Analysis 10.2</a> and <a href="./references#CD013750-fig-0041" title="">Analysis 10.3</a>). </p> </li> <li> <p>Of the 13 treatment‐comparisons included in this review, five were results from trials not specifically assessing mTNBC patients (i.e. mTNBC patients were part of a subgroup analysis; <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>; <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>; <a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a>; <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>; <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>). Of these five treatment‐comparisons, four were included in meta‐analyses (<a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> were included in meta‐analyses for PFS/TTP and <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> and <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> were included in meta‐analyses for OTRR). Sensitivity analysis indicated that the two very small treatment‐comparisons <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>and <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> had very little influence on the original OTRR pooled estimate (RR 1.40, 95% CI 1.22 to 1.59 when including <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>and <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> and RR 1.39, 95% CI 1.21 to 1.59 after excluding <a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a>and <a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a>) (<a href="./references#CD013750-fig-0044" title="">Analysis 11.3</a>). With regard to <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>, sensitivity analysis indicated that these two treatment‐comparisons had PFS/TTP effect estimates more favourable to platinum than those of the other six treatment‐comparisons in the PFS/TTP meta‐analyses (P = 0.001; <a href="./references#CD013750-fig-0043" title="">Analysis 11.2</a>). Despite this, the PFS/TTP pooled estimate did not change appreciably when <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> were excluded (HR 0.77, 95% CI 0.68 to 0.88 when including <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> and HR 0.82, 95% CI 0.72 to 0.94 after excluding <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> and <a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>). These results suggest our main findings were not appreciably affected by the inclusion of trials in which the analysis of mTNBC patients was part of a subgroup analysis. </p> </li> <li> <p>Removal of the trial that used a drug which is now widely considered to be ineffective in the treatment of breast cancer (<a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>) had little effect on the OS, PFS/TTP and OTRR point estimates of effect (<a href="./references#CD013750-fig-0045" title="">Analysis 12.1</a>; <a href="./references#CD013750-fig-0046" title="">Analysis 12.2</a>; <a href="./references#CD013750-fig-0047" title="">Analysis 12.3</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013750-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013750-sec-0065"></div> <section id="CD013750-sec-0066"> <h3 class="title" id="CD013750-sec-0066">Summary of main results</h3> <p>Consistent with the findings of the mTNBC subgroup analysis in our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>), we found in our current review a marginal OS benefit from platinum‐containing regimens compared to non‐platinum regimens. Specifically, data from six treatment‐comparisons included in the OS meta‐analysis showed a 15% reduction in the risk of death for recipients of platinum‐containing regimens compared to recipients of non‐platinum regimens (P = 0.05). In absolute terms, this 15% risk reduction corresponded to about 55 fewer deaths at one year after metastatic diagnosis for every 1000 mTNBC participants who received platinum‐containing chemotherapy, and about 59 fewer deaths at two years (<a href="./full#CD013750-tbl-0001">summary of findings Table 1</a>). Supporting the observed benefit from platinum in terms of OS, platinum‐containing regimens also reduced the risk of death and/or progression (PFS/TTP) by about 23% (P &lt; 0.0001) and increased the likelihood of achieving a complete or partial response (OTRR) by about 40% (P &lt; 0.00001). Moreover, sensitivity analyses suggested that the absence of some treatment‐comparisons from the OS meta‐analysis may have led to an underestimate of the benefit of platinum regimens in terms of OS. While we found a number of statistically significant subgroup differences for OTRR and PFS/TTP (see <a href="#CD013750-sec-0050">Effects of interventions</a>), it is difficult to judge the importance or reliability of these findings, given that similar differences were not observed in relation to OS. </p> <p>It is worth noting that the largest trial, <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> did not find an OS, PFS or OTRR advantage for women with mTNBC receiving carboplatin (versus docetaxel). However, in subgroup analysis restricted to 43 BRCA1/2 positive participants, <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> found carboplatin was associated with significantly better OTRRs and PFS/TTP. Of the 43 BRCA1/2 positive participants, only 14 (33%) had TNBC, and the remaining 29 (66%) were ER positive, PgR positive and/or HER2 positive (the more common breast cancer clinical subtypes). This suggests that the apparent benefits of platinum for mTNBC patients might be, at least in part, due to the presence of BRCA1/2 mutations in many mTNBC patients, rather than due to the triple‐negative subtype. Furthermore, in the only included trial where 100% of participants were BRCA1/2 positive (<a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>/<a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a>), subgroup analysis indicated that the PFS benefits from the two platinum regimens were similar between mTNBC patients and non‐mTNBC patients. Taken together, the findings of <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> and <a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a>/<a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> and the significant subgroup differences according to BRCA1/2 germline mutation status for PFS/TTP and OTRR (which also included results from <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>) highlight the importance of performing BRCA1/2 subgroup analysis in future trials assessing platinum chemotherapies for mTNBC patients. </p> <p>In addition to the BRCA1/2 findings of <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>, the trial is noteworthy in that it was the largest in this review, it did not find an OS advantage for women with mTNBC receiving carboplatin, and the platinum group performed worst (relative to control) among all trials in this review in terms of PFS and OTRR. Moreover, much of the observed heterogeneity for the PFS and OTRR outcomes appears to be driven by the estimates from <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>. While it is not clear why the platinum arm faired relatively poorly in <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>, the trial was the only one to use single agent platinum (carboplatin) in the intervention arm and the only trial to use single agent docetaxel in the control arm. </p> <p>Another subgroup finding of interest was that the relative benefits of platinum in terms of PFS/TTP and OTRR were greater for trials with 'second‐ or third‐line therapy for ≥ 20% of patients' than for trials with 'first‐line therapy for &gt; 80% of patients' (although this subgroup difference was not observed for the OS outcome). This finding suggests that platinum based regimens may be an effective treatment option following first‐line therapy for mTNBC. </p> <p>Assessments of toxicity showed that women receiving platinum‐containing regimens experienced higher rates of grade 3 and 4 nausea/vomiting and anaemia than women receiving non‐platinum regimens, but no differences between treatment groups in terms of treatment related death, or grade 3 and 4 hair loss, leukopaenia and treatment discontinuation due to adverse event. In general, however, relatively few intervention‐comparisons could be included in meta‐analyses for adverse events. Better evidence of the toxicity of platinum regimens compared to non‐platinum regimens can be found in our previous analysis (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) of adverse events in women with metastatic breast cancer unselected for TNBC. In this regard, our previous review indicated that women receiving platinum‐containing regimens experienced higher rates of grade 3 and 4 nausea/vomiting, anaemia and leukopaenia. More specifically, the higher rate of grade 3 and 4 nausea/vomiting was associated with cisplatin but not carboplatin use, and the increased risk of grade 3 and 4 anaemia was higher for cisplatin recipients than for carboplatin recipients. However, it is likely that newer antiemetics might now lessen the severity of cisplatin‐associated nausea and vomiting. In addition, our previous review also reported that women receiving platinum‐containing regimens experienced a higher rate of grade 3 and 4 hair loss than women receiving non‐platinum regimens. This finding, however, probably relates more to the partner chemotherapy agent than to the platinum itself, as single agent platinum chemotherapies tend not to cause much hair loss. </p> </section> <section id="CD013750-sec-0067"> <h3 class="title" id="CD013750-sec-0067">Overall completeness and applicability of evidence</h3> <p>This review includes data from 10 studies relating to 13 treatment‐comparisons, with publications years ranging from 2005 to 2018. Of the 13 treatment‐comparisons, six (46%), eight (62%) and 10 (77%) provided sufficient data to be included in OS, PFS/TTP and OTRR meta‐analyses, respectively. In general, the number of treatment‐comparisons that had sufficient data on adverse events for mTNBC patients was low, including treatment‐related death (n = 5; 38%), nausea/vomiting (n = 3; 75%), nephrotoxicity (n = 0; 0%), anaemia (n = 5; 38%), hair loss (n = 2; 15%), leukopaenia (n = 5; 38%) and treatment discontinuation due to adverse events (n = 5; 38%). The evidence relating to treatment effects on QoL was wholly incomplete, with no studies reporting QoL results for mTNBC patients. </p> <p>Although data for the most important outcome (OS) could be included in meta‐analysis for 46% of treatment‐comparisons, the evidence would clearly be more complete if OS data were available for all treatment‐comparisons. Nonetheless, it is somewhat reassuring that in sensitivity analyses, the treatment‐comparisons with PFS/TTP or OTRR data that were not included in the OS meta‐analysis tended to show a greater benefit to platinum in terms of PFS/TTP and/or OTRR results than the six treatment‐comparisons included in the OS meta‐analysis. This provides some evidence that the 'overall' pooled effect estimate for OS was unlikely to show less benefit to platinum if OS data had been available for all 12 treatment‐comparisons that were included in one or more meta‐analyses. </p> <p>The evidence in this review appears to be generally applicable to the current practice of the treatment of mTNBC for a number of reasons. First, the platinum and non‐platinum regimens used in the included trials contained commonly used chemotherapy drugs currently used in clinical practice to treat metastatic breast cancer including cyclophosphamide, methotrexate and various taxanes. On the other hand, the applicability of the evidence is somewhat reduced by the fact that no trials included an anthracycline (a commonly used class of drug for the treatment mTNBC) in their non‐platinum regimens. Second, the review included trials of women receiving first‐line treatment and women receiving treatment after failure of previous anthracycline or taxane regimens. Third, the trials in the review used the two most commonly used platinum agents for treating metastatic breast cancer, carboplatin and cisplatin. Fourth, this review and our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) are, to date, the only reviews to use meta‐analysis to synthesise the evidence from RCTs assessing whether platinum‐based chemotherapies improved OS for mTNBC participants. </p> </section> <section id="CD013750-sec-0068"> <h3 class="title" id="CD013750-sec-0068">Quality of the evidence</h3> <p>We downgraded the quality of the evidence for the OS effect estimate by one level resulting in moderate‐quality evidence. This was due to imprecision (the CI for the pooled estimate was wide and close to the null) (<a href="./full#CD013750-tbl-0001">summary of findings Table 1</a>). This rating of moderate‐quality evidence for OS has improved from low‐quality evidence in our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) because the largest study (<a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a>) has now published previously unpublished OS results. This lowered the risk of publication bias for the OS pooled estimate. The quality of the evidence ratings for PFS/TTP and OTRR were downgraded one level for indirectness (because the outcome is a surrogate endpoint) and one level for inconsistency (because there was substantial evidence of heterogeneity). The rating for PFS/TTP was further downgraded one level for suspected publication bias (forest plot asymmetry). As a consequence, we judged the quality of the evidence to be very low for PFS/TTP and low for OTRR. </p> <p>We graded the quality of evidence for treatment effect estimates of seven key toxicity outcomes (<a href="./full#CD013750-tbl-0002">summary of findings Table 2</a>). We judged the quality of evidence to be low for treatment‐related death, nausea/vomiting, anaemia and hair loss. Evidence quality was moderate for leukopaenia and treatment discontinuation due to adverse events. As mentioned above, however, because few treatment‐comparisons could be included in meta‐analyses for adverse events, better evidence of the toxicity of platinum regimens compared to non‐platinum regimens should be found in our previous analysis (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) of adverse events in women with metastatic breast cancer unselected for TNBC. However, many studies in that analysis were older trials. </p> </section> <section id="CD013750-sec-0069"> <h3 class="title" id="CD013750-sec-0069">Potential biases in the review process</h3> <p>There were a number of potential biases in the review process. First, it is possible that we may not have identified every eligible study with published results, study protocol or clinical trial registration. This seems unlikely, however, given our highly sensitive search strategies, including access to the Cochrane Breast Cancer Specialised Register maintained by the Cochrane Breast Cancer Group. Second, as with all systematic reviews of clinical trials, there is a risk of reporting bias arising from completed trials that never published their (largely) negative findings (i.e. publication bias). In this review, however, all but one of the included studies were conducted in an era when non‐publication of negative findings was less likely (i.e. due to increasing pressures to pre‐register clinical trials and publish results within reasonable time‐frames). Third, it is possible that trials not specifically assessing mTNBC patients might be more inclined to publish significant mTNBC results from a subgroup analysis that was not pre‐specified in the trial protocol or trial registration. In this review, however, sensitivity analyses indicated that our main results were not appreciably affected by the inclusion of trials in which the analysis of mTNBC patients was part of a post‐hoc subgroup analysis. </p> </section> <section id="CD013750-sec-0070"> <h3 class="title" id="CD013750-sec-0070">Agreements and disagreements with other studies or reviews</h3> <p>Included in the mTNBC subgroup meta‐analyses of our previous review (<a href="./references#CD013750-bbs2-0039" title="EggerSJ , WillsonML , MorganJ , WalkerHS , CarrickS , GhersiD , et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD003374. [DOI: 10.1002/14651858.CD003374.pub4]">Egger 2017</a>) were three treatment‐comparisons of 391 women for OS, three treatment‐comparisons of 391 women for PFS/TTP and five treatment‐comparisons of 878 women for OTRR. In the current review, these numbers increased to six treatment‐comparisons of 958 women for OS, eight treatment‐comparisons of 1077 women for PFS/TTP and 10 treatment‐comparisons of 1205 women for OTRR. </p> <p>In our previous review, we found that for women with mTNBC, platinum‐containing regimens provided benefits in terms of OS (HR 0.75, 95% CI 0.57 to 1.00; low‐quality evidence), PFS/TTP (HR 0.59, 95% CI 0.49 to 0.72; low‐quality evidence) and OTRR (RR 1.33, 95% CI 1.13 to 1.56; low‐quality evidence). In the current review, we found similar, but smaller, benefits for platinum recipients in terms of OS (HR 0.85, 95% CI 0.73 to 1.00; moderate‐quality evidence) and PFS/TTP (HR 0.77, 95% CI 0.68 to 0.88; 1077 women; very low‐quality evidence), and similar, but slightly larger, benefits for platinum recipients in terms of OTRR (RR 1.40, 95% CI 1.22 to 1.59; low‐quality evidence). As a general statement, the findings in this review are similar to the mTNBC‐specific findings in our previous review. </p> <p>To our knowledge, there is only one other systematic review of randomised trials comparing the effects of platinum and non‐platinum‐containing regimens among participants with mTNBC (<a href="./references#CD013750-bbs2-0045" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anti-cancer Drugs2015;26(8):894-901.">Guan 2015</a>). That review, however, only performed meta‐analyses of tumour response rates and not time‐to‐event outcomes. The OTRR meta‐analysis in <a href="./references#CD013750-bbs2-0045" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anti-cancer Drugs2015;26(8):894-901.">Guan 2015</a> comprised three of the 10 mTNBC treatment‐comparisons included in the current review (<a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a>; <a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a>). The inclusion of seven additional treatment‐comparisons in the current review resulted in a pooled OTRR estimate of effect (RR 1.40, 95% CI 1.22 to 1.59) that is significantly lower than that of <a href="./references#CD013750-bbs2-0045" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anti-cancer Drugs2015;26(8):894-901.">Guan 2015</a> (RR 2.42, 95% CI 1.66 to 3.53). </p> <p>While another systematic review also found significant OS and PFS benefits for mTNBC patients who received platinum (<a href="./references#CD013750-bbs2-0053" title="KayaV , YildirimM , YaziciG , GunduzS , BozcukH , PaydasS . Effectiveness of platinum-based treatment for triple negative metastatic breast cancer: a meta-analysis. Asian Pacific journal of cancer prevention2018;19(5):1169.">Kaya 2018</a>), this review included observational studies and did report RCT‐specific results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013750-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Review 2020: study flow diagram." data-id="CD013750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review 2020: study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for PFS/TTP (Progression‐free survival/time to progression). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for PFS/TTP that could be included in meta‐analysis. The plot suggests some level of asymmetry (Egger's test P value = 0.02)." data-id="CD013750-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot for PFS/TTP (Progression‐free survival/time to progression). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for PFS/TTP that could be included in meta‐analysis. The plot suggests some level of asymmetry (Egger's test P value = 0.02). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OS that could be included in meta‐analysis.. The plot does not show substantial asymmetry (Egger's test P value = 0.08)" data-id="CD013750-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OS that could be included in meta‐analysis.. The plot does not show substantial asymmetry (Egger's test P value = 0.08) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for objective tumour response rate (OTRR). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OTRR that could be included in meta‐analysis. The plot does not show asymmetry (Egger's test P value = 0.12)." data-id="CD013750-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot for objective tumour response rate (OTRR). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with data for OTRR that could be included in meta‐analysis. The plot does not show asymmetry (Egger's test P value = 0.12). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.1 Overall survival." data-id="CD013750-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.2 Progression‐free survival/time to progression." data-id="CD013750-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.3 Objective tumour response rate (assessable participants)." data-id="CD013750-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens, outcome: 1.3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Platinum vs non‐platinum regimens, Outcome 1: Overall survival" data-id="CD013750-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Platinum vs non‐platinum regimens, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Platinum vs non‐platinum regimens, Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Platinum vs non‐platinum regimens, Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Platinum vs non‐platinum regimens, Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Platinum vs non‐platinum regimens, Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 1: Overall survival" data-id="CD013750-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 1: Overall survival" data-id="CD013750-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 4: Treatment‐related death (safety population)" data-id="CD013750-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 4: Treatment‐related death (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 5: Nausea/vomiting (safety population)" data-id="CD013750-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 5: Nausea/vomiting (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 6: Anaemia (safety population)" data-id="CD013750-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 6: Anaemia (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 7: Hair loss (safety population)" data-id="CD013750-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 7: Hair loss (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 8: Leukopenia (safety population)" data-id="CD013750-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 8: Leukopenia (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 9: Treatment discontinuation due to adverse event (safety population)" data-id="CD013750-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm), Outcome 9: Treatment discontinuation due to adverse event (safety population) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 1: Overall survival" data-id="CD013750-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 1: Overall survival" data-id="CD013750-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 1: Overall survival" data-id="CD013750-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 1: Overall survival" data-id="CD013750-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis), Outcome 1: Progression‐free survival/time to progression" data-id="CD013750-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis), Outcome 1: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis), Outcome 2: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis), Outcome 2: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression), Outcome 1: Progression‐free survival vs time to progression" data-id="CD013750-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression), Outcome 1: Progression‐free survival vs time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 1: Overall survival" data-id="CD013750-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 1: Overall survival" data-id="CD013750-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 1: Overall survival" data-id="CD013750-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 2: Progression‐free survival/time to progression" data-id="CD013750-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 2: Progression‐free survival/time to progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013750-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/urn:x-wiley:14651858:media:CD013750:CD013750-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 3: Objective tumour response rate (assessable participants)" data-id="CD013750-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_t/tCD013750-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 3: Objective tumour response rate (assessable participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013750/media/CDSR/CD013750/image_n/nCD013750-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013750-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum compared to non‐platinum regimens for metastatic triple‐negative breast cancer: OS, PFS/TTP and OTRR</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> platinum<br/><b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platinum containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.85<br/>(0.73 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>958<br/>(6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: Chi² = 5.05, df = 5 (P = 0.41); I² 1%</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>510 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>455 per 1,000<br/>(406 to 510)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>711 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1,000<br/>(596 to 711)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (PFS/TTP)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of progression or death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.77<br/>(0.68 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1077<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: Chi² = 34.78, df = 7 (P &lt; 0.0001); I² 80%</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>936 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>880 per 1,000<br/>(846 to 911)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2‐year risk of progression or death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>970 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1,000<br/>(908 to 954)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (OTRR) (assessable participants)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1,000 <sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1,000<br/>(449 to 585) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(1.22 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1205<br/>(10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: Chi² = 21.44, df = 9 (P = 0.01); I² 58%</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b> (⊕⊕⊕⊕): We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> (⊕⊕⊕⊝)<b>:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> (⊕⊕⊝⊝)<b>:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b> (⊕⊝⊝⊝ or ⊝⊝⊝⊝)<b>:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p>Each ⊝ symbol represents a downgrading of the quality of evidence one level from the highest level of 'high quality (⊕⊕⊕⊕).' </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the 3 highest weighted treatment‐comparisons in <a href="./references#CD013750-fig-0009" title="">Analysis 1.1</a>. </p> <p><sup>2</sup>Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD013750-bbs2-0046" title="GuyattGH , JuniperEF , WalterSD , GriffithLE , GoldsteinRS . Interpreting treatment effects in randomised trials. BMJ 1998 Feb 28;316(7132):499-501.">Guyatt 1998</a>) </p> <p><sup>3</sup>Downgraded quality of evidence one level for ’serious imprecision’ because the confidence interval for the pooled estimate is wide and crosses or nearly crosses unity. </p> <p><sup>4</sup>Downgraded quality of evidence one level for ’serious indirectness’ because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD013750-bbs2-0034" title="BurzykowskiT , BuyseM , Piccart-GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987-92.">Burzykowski 2008</a>). </p> <p><sup>5</sup>Downgraded quality of evidence one level for ’serious inconsistency’ because there was substantial evidence of heterogeneity. </p> <p><sup>6</sup>Downgraded quality of evidence one level for suspected publication bias (forest plot asymmetry). </p> <p><sup>7</sup>Estimated from all 10 mTNBC treatment‐comparisons in the review with OTRR results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum compared to non‐platinum regimens for metastatic triple‐negative breast cancer: OS, PFS/TTP and OTRR</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013750-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for treatment related death, nausea/vomiting, nephrotoxicity, anaemia, hair loss, leuko</b> paenia<b>and treatment discontinuation due to adverse event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> platinum<br/><b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platinum containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐related death (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1,000<br/>(1 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 1.06, 95% CI 0.24 to 4.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.69, I<sup>2</sup> 0% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting* grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/>(29 to 177) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(RR 4.77, 95% CI 1.93 to 11.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>655 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.32, I<sup>2</sup> 12% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nephrotoxicity (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trials reported this outcome for mTNBC patients.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaemia grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000<br/>(81 to 231) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(RR 3.80, 95% CI 2.25 to 6.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.04, I<sup>2</sup> 65% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hair loss (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1,000<br/>(0 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 0.33, 95% CI 0.01 to 8.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopaenia (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>155 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>169 per 1000 (130 to 220)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 1.09, 95% CI 0.84 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.75, I<sup>2</sup> 0% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment discontinuation due to adverse event (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>93 per 1000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 1000 (55 to 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(RR 0.88, 95% CI 0.59 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity: P = 0.07, I<sup>2</sup> 57% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> (⊕⊕⊕⊕): We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> (⊕⊕⊕⊝)<b>:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> (⊕⊕⊝⊝)<b>:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b> (⊕⊝⊝⊝ or ⊝⊝⊝⊝)<b>:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p>Each ⊝ symbol represents a downgrading of the quality of evidence one level from the highest level of 'high quality (⊕⊕⊕⊕).' </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Estimated from all treatment‐comparisons contributing data for pooling for this outcome (including treatment‐comparisons with non‐estimable effects due to no events in either arm). </p> <p><sup>2</sup>Downgraded quality of evidence one level for 'serious imprecision' because the confidence interval for the pooled estimate is wide. </p> <p><sup>3</sup>Downgraded quality of evidence two levels for 'very serious imprecision' because the confidence interval for the pooled estimate is very wide. </p> <p><sup>4</sup>Downgraded quality of evidence one level for 'serious inconsistency' because there was evidence of heterogeneity across studies (P &lt; 0.05) </p> <p>*data on vomiting was included if data on nausea/vomiting was reported separately</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013750-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Common platinum agents</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Generic name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other names</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, Nealorin, Novoplatinum, Paraplat, Paraplatin AQ, Paraplatin, Paraplatine, Platinwas, Ribocarbo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abiplatin, Blastolem, Briplatin,CACP, CDDP, cis‐DDP, cis‐diamminedichloridoplatinum, cis‐diamminedichloro platinum (II), cis‐diamminedichloroplatinum, Cis‐dichloroammine Platinum (II), Cismaplat, Cisplatina, cis‐platinous diamine dichloride, cis‐platinum II diamine dichloride, cis‐platinum II, cis‐platinum, Cisplatyl, Citoplatino, Citosin, CPDD, Cysplatyna, DDP, DDP, Lederplatin, Metaplatin, Neoplatin, PDD, Peyrone's Chloride, Peyrone's Salt, Placis, Platamine, Platiblastin, Platiblastin‐S, Platinex, Platinol‐ AQ, Platinol, Platinol‐AQ VHA Plus, Platinol‐AQ, Platinoxan, platinum diamminodichloride, Platiran, Platistin, Platosin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ai Heng, Aiheng, diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum, oxaliplatine, Eloxatin, Dacotin, Dacplat, Eloxatine, 1‐OHP, L‐OHP, oxaliplatin medac </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Common platinum agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013750-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of Agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Includes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agents that damage the DNA template</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrogen mustards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, melphalan, ifosfamide, chlorambucil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrosureas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>carmustine (BCNU), lomustine (CCNU)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: other agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thiotepa, mitomycin C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by platinum coordination cross‐linking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cisplatin, carboplatin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>doxorubicin, daunorubicin, mitoxantrone, idarubicin, epirubicin, amsacrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>podophyllotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>etoposide, teniposide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by intercalation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dactinomycin, mithramycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by uncertain mechanisms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bleomycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spindle poisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vinca alkaloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vincristine, vinblastine, vendesine, vinorelbine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxanes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxol, taxotere</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antimetabolites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thymidylate synthase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydrofolate reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013750-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons by subgroup and three outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Treatment‐</b> </p> <p><b>comparisons</b> </p> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Overall</b> </p> <p><b>survival</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Progression</b> </p> <p><b>‐free</b> </p> <p><b>survival/time to</b> </p> <p><b>progression</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Objective</b> </p> <p><b>tumour</b> </p> <p><b>response</b> </p> <p><b>rate</b> </p> <p><b>n (% of N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Overall:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (46%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8 (62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10 (77%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Type of regimen comparison:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Regimen A + platinum agent vs regimen A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Regimen A + platinum agent vs regimen B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (44%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7 (78%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Single agent platinum vs regimen C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Type of platinum agent in platinum arm:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cisplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (29%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (29%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Carboplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (67%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>First‐line therapy:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>First‐line therapy for &gt; 80% of patients</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5 (83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Second‐ or third‐line therapy for &gt;=20% of patients</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (14%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (43%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (57%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Anthracycline in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6 (46%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8 (62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10 (77%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Taxane in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No taxane in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (80%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum + taxane vs non‐platinum + non‐taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>BRCA1/2 subtype:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Germline BRCA1/2 mutation #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germline BRCA1/2 wild‐type #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Homologous recombination deficiency status:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homologous recombination deficient #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not homologous recombination deficient #</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>1 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2 (100%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>^Numbers for each outcome are the number of treatment‐comparison with sufficient data to be included in meta‐analysis for that outcome. </p> <p># BRCA1/2 subtype and homologous recombination deficiency status were within‐study subgroupings for <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> and <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a>; hence <a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> and <a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> both contributed to both BRCA1/2 subroups and both homologous recombination deficiency status subgroups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons by subgroup and three outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013750-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trials ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 1</b> <b>(platinum‐containing)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 2</b> <b>(control)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line therapy for &gt; 80% of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Majority participants anthracycline‐naive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Endoxan + with 'cisplatinum')</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Endoxan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C + Cb (Cetuximab + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (Cetuximab with carboplatin added after progression)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (docetaxel + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TX (docetaxel + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCP (placebo + carboplatin/paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VT (veliparib + temozolomide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCP (eliparib + carboplatin/paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VT (veliparib + temozolomide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemVin (gemcitabine + vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCap (gemcitabine + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/C (nab‐paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/G (nab‐paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G/C (gemcitabine + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nab‐P/G (nab‐paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D (docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013750-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS data useable for HR estimation for mTNBC patients<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> <b>OS time for mTNBC patients<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PFS/TTP data useable for HR estimation for mTNBC patients<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median PFS/TTP time for mTNBC patients<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective tumour response for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related deaths for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade III &amp; IV Toxicity for mTNBC patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0001" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. In: European Journal of Cancer Supplements. Vol. 7. 2009:18-19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0002" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology2012;30(21):2615-23. NCT00232505. Cetuximab + / - carboplatin for estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not useable for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0003" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0007" title="MustafaS , ZamzamM , Abdel MohsenS , HassanenE . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer. The Egyptian Journal of Hospital Medicine2019;74(8):1878-83. ">Mustafa 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not useable for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0004" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2017;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0005" title="HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , JagerA , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology 2017 Sep 29;29(1):154-61. NCT01506609. The study evaluating efficacy and tolerability of veliparib in combination with temozolomide or in combination with carboplatin with and paclitaxel versus placebo in subjects with BRCA1 and BRCA2 mutation and metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT01506609 (accessed July 30 2019). ">Han 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0008" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0009" title="NCT00480597. Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071-8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0011" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology2018;29(8):1763-70. ">Yardley 2018 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0012" title="NCT01881230. Evaluate risk/beneift of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity). https://clinicaltrials.gov/ct2/show/NCT01881230 (accessed July 30 2019). YardleyDA , BrufskyA , ConteP , CortesJ , GlückS , Nabholtz J-MA, et al. TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research2013;73(24 Supplement):OT3. YardleyDA , ColemanR , ConteP , CortesJ , BrufskyA , ShtivelbandM , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology 2018 Jun 6;29(8):1763-70. ">Yardley 2018 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0013" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436-46. NCT01287624. Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ZhangJ , LinY , SunXJ , WangBY , WangZH , LuoJF , et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology2018;29(8):1741-7. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0006" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002;13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639-44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopaenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013750-bbs2-0010" title="NCT00532727. Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3-01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip-negative or BRCA1/2 breast cancer. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Vol. 75. 2014:S3-1. TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine2018;24(5):628-41. ">Tutt 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopaenia</p> <p>Treatment‐discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup>Sufficient data reported to estimate a HR for pooling as outlined by <a href="./references#CD013750-bbs2-0056" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a> and <a href="./references#CD013750-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):1.">Tierney 2007</a>; this includes Kaplan‐Meier curve, HR and standard error/confidence interval or logrank statistics<br/><sup>2</sup>Trials that did not explicitly report median time were classified as NR here regardless of estimable median time from Kaplan‐Meier curve<br/><sup>3</sup>Analysed numbers represent the maximum numbers of participants in the treatment‐comparison that were included in a meta‐analysis of OS, PFS/TTP or OTRR (assessable participants). </p> <p>DU: deaths unexplained<br/>NR: not reported at all or not reported for mTNBC subgroup<br/>OS: overall survival<br/>PFS: progression‐free survival<br/>TTP: time to progression<br/>Y: year reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/full#CD013750-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Platinum vs non‐platinum regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Platinum vs non‐platinum regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Regimen A + platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Regimen A + platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Single agent platinum vs regimen C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Regimen A + platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.41, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Regimen A + platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.55, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Single agent platinum vs regimen C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Regimen A + platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.42, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Regimen A + platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.29, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Single agent platinum vs regimen C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 1: by type of regimen comparison)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.36, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.93, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Treatment‐related death (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.24, 4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.24, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Nausea/vomiting (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [1.93, 11.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.89 [2.08, 56.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.79, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Anaemia (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.25, 6.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [2.86, 14.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.11, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Hair loss (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Leukopenia (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.79, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.58, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Treatment discontinuation due to adverse event (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.60, 1.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.38, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.13, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.42, 2.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 3: by first‐line therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.38, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.77, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 Platinum + taxane vs non‐platinum + non‐taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.41, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Platinum + taxane vs non‐platinum + non‐taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.42, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.48, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.4 Platinum + taxane vs non‐platinum + non‐taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 4: by taxane in regimens)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 germline BRCA1/2 mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.62, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 germline BRCA1/2 wild‐type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 germline BRCA1/2 mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.30, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 germline BRCA1/2 wild‐type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.93, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 germline BRCA1/2 mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.17, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 germline BRCA1/2 wild‐type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 5: BRCA1/2 mutation status)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.62, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 not homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 not homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.81, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 not homologous recombination deficient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.72, 1.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Included in OS meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Not included in OS meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Included in OS meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.11, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Not included in OS meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.33, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 1: included in OS meta‐analysis vs. not included in OS meta‐analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Progression‐free survival vs time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Progression‐free survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.41, 0.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.45, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.17, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Trial designed to specifically assess mTNBC patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 mTNBC patients were part of a subgroup analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Trial designed to specifically assess mTNBC patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 mTNBC patients were part of a subgroup analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Trial designed to specifically assess mTNBC patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.21, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 mTNBC patients were part of a subgroup analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.76, 3.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 4: mTNBC patients selected for trial vs. a subgroup of trial)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013750-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.21, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013750/references#CD013750-tbl-0019">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013750&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013750-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013750-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013750-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013750-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013750-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013750-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013750-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013750-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013750-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013750"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013750"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013750"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013750\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013750\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013750"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013750&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013750';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013750/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013750/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013750%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724528694"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013750/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724528698"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013750/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6508d9a3f44a',t:'MTc0MDcyNDUyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 